UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 10-Q

  

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2017March 31, 2020

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 001-37941

  

SENESTECH, INC. 

(Exact name of registrant as specified in its charter)

  

Delaware 20-2079805

(State or other jurisdiction of


incorporation or organization)

 

(I.R.S. Employer


Identification No.)

   
23460 N. 19th Avenue, Suite 110
3140 N. Caden Court, Suite 1Phoenix, AZ
Flagstaff, AZ
 8600485027
(Address of principal executive offices) (Zip Code)

 

(928) 779-4143

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each classTrading Symbol(s)Name of each exchange on which
registered
Common Stock, $0.001 par valueSNESThe NASDAQ Stock Market LLC
(NASDAQ Capital Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filerAccelerated filer
Non-accelerated filer ☐(Do not check if a smaller reporting company) Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

 

The number of shares of common stock outstanding as of November 7, 2017: 10,389,497May 14, 2020: 3,394,955

 

 


 

SENESTECH, INC.

FORM 10-Q

For the Quarterly Period Ended September 30, 2017March 31, 2020

 

TABLE OF CONTENTS

 

  Page
 PART I. FINANCIAL INFORMATION3
Item 1Financial Statements31
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations28
Item 3Quantitative and Qualitative Disclosures About Market Risk3938
Item 4Controls and Procedures39
PART II. OTHER INFORMATION39
Item 1ARisk Factors39
Item 5Other Information40
Item 6Exhibits41
Index to Exhibits4138
 SignaturesPART II. OTHER INFORMATION42
Item 1Legal Proceedings39
Item 1ARisk Factors39
Item 2Unregistered Sales of Equity Securities and Use of Proceeds39
Item 3Defaults Upon Senior Securities39
Item 4Mine Safety Disclosures39

i

 


 

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements

 

Item 1.       Financial Statements

SENESTECH, INC.

CONDENSED BALANCE SHEETS

(In thousands, except shares and per share data)

 

 March 31, December 31, 
 September 30,
2017
  December 31,
2016
  2020 2019 
ASSETS  (Unaudited)   (Unaudited)   
             
Current assets:             
Cash $699  $11,826  $1,492  $1,936 
Investment in securities held to maturity  2,949    
Accounts receivable  7   10 
Accounts receivable trade, net  22   26 
Accounts receivable-other  -   123 
Prepaid expenses  172   337   297   257 
Inventory  394   57   1,162   1,180 
Deposits  17   9   18   20 
Total current assets  4,238   12,239   2,991   3,542 
                
Right to use asset-operating leases  622   699 
Property and equipment, net  1,559   631   636   738 
Total assets $5,797  $12,870  $4,249  $4,979 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                
Current liabilities:                
Short-term debt $174  $45  $116  $123 
Accounts payable  175   351   739   265 
Accrued contract cancellation settlement     1,000 
Accrued expenses  1,074   371   600   1,193 
Notes payable, related parties  18   30 
Total current liabilities  1,441   1,797   1,455   1,581 
                
Notes payable, related parties     6 
Long-term debt, net  637   138   96   137 
Common stock warrant liability  4   69 
Deferred rent  45   33 
Operating lease liability  624   694 
Total liabilities  2,127   2,043   2,175   2,412 
                
Commitments and contingencies (See note 15)      
Commitments and contingencies (See note 12)  -   - 
                
Stockholders’ equity:                
        
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,363,189 and 10,157,292 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively  10   10 
Common stock, $0.001 par value, 100,000,000 shares authorized, 1,819,981 and 1,414,671 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively  2   1 
Additional paid-in capital  74,946   72,069   100,670   98,433 
Stock subscribed, but not issued, consisting of -0- and 4,750 shares at September 30, 2017 and December 31, 2016, respectively     59 
Accumulated deficit  (71,286)  (61,311)  (98,598)  (95,867)
Total stockholders’ equity  3,670   10,827   2,074   2,567 
                
Total liabilities and stockholders’ equity $5,797  $12,870  $4,249  $4,979 

See accompanying notes to financial statements. 


SENESTECH, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except shares and per share data)

(Unaudited)

  For the Three Months 
  Ended March 31, 
  2020  2019 
Revenue:      
Sales $37  $19 
Cost of sales  22   12 
Gross profit  15   7 
         
Operating expenses:        
Research and development  296   464 
Selling, general and administrative  2,045   1,904 
Total operating expenses  2,341   2,368 
         
Net operating loss  (2,326)  (2,361)
         
Other income (expense):        
Interest income  2   15 
Interest expense  (8)  (13)
Other income (expense)  15   (5)
Total other income (expense)  9   (3)
         
Net loss and comprehensive loss  (2,317)  (2,364)
Deemed dividend-warrant price protection-revaluation adjustment  414   - 
Net loss attributable to common shareholders $(2,731) $(2,364)
         
Weighted average common shares outstanding - basic and fully diluted  1,611,304   1,175,920 
         
Net loss per common share - basic and fully diluted $(1.69) $(2.01)

  

See accompanying notes to financial statements.


SENESTECH, INC.

CONDENSED STATEMENTSSTATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except shares and per share data)

(Unaudited)

 

  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
 
  2017  2016  2017  2016 
Revenue:            
License revenue $  $131  $  $261 
Product Sales  17      34    
Total revenue  17   131   34   261 
Cost of goods sold  11      27    
Gross profit  6   131   7   261 
                 
Operating expenses:                
Research and development  721   829   2,517   1,964 
General and administrative  2,235   1,932   7,506   5,259 
Total operating expenses  2,956   2,761   10,023   7,223 
                 
Net operating loss  (2,950)  (2,630)  (10,016)  (6,962)
                 
Other income (expense):                
Interest income  9      20    
Interest expense  (33)  (6)  (54)  (49)
Interest expense, related parties     (9)  (1)  (43)
Loss on extinguishment of unsecured promissory note     (59)     (171)
Other income (expense)  37      76   51 
Total other income (expense)  13   (74)  41   (212)
                 
Net loss  (2,937)  (2,704)  (9,975)  (7,174)
                 
Series A convertible preferred stock dividends     (30)     (90)
                 
Net loss and comprehensive loss $(2,937) $(2,734) $(9,975) $(7,264)
                 
Weighted average common shares outstanding - basic and fully diluted  10,334,211   7,306,234   10,234,211   5,774,738 
                 
Net loss per common share - basic and fully diluted $(0.28) $(0.37) $(0.97) $(1.26)
        Additional     Total 
  Common Stock  Paid-In  Accumulated  Stockholders’ 
  Shares  Amount  Capital  Deficit   Equity (Deficit) 
Balance, December 31, 2018  1,173,854  $1  $92,151  $(85,838) $6,314 
                     
Issuance of common stock for services  1,929   -   32   -   32 
Stock-based compensation  -   -   252   -   252 
Issuance of common stock upon exercise of warrants  1,591   -   36   -   36 
Issuance of common stock upon cashless exercise of stock options  924   -   -   -   - 
Net loss for the three months ended March 31, 2019  -   -   -   (2,364)  (2,364)
                     
Balance, March 31, 2019  1,178,297  $1  $92,471  $(88,202) $4,270 
                     
Balance, December 31, 2019  1,414,671  $1  $98,433  $(95,867) $2,567 
                     
Stock based compensation  -   -   151   -   151 
Issuance of common stock, sold for cash, net  353,872   1   1,707   -   1,708 
Issuance of common stock upon exercise of warrants  51,414   -   238   -   238 
Issuance costs of common stock issuances          (273)      (273)
Issuance of common stock for fractional shares-20-1 reverse split  24   -   -   -   - 
Warrant antidilution price protection adjustment          414       414 
Net loss for the three months ended March 31, 2020  -   -   -   (2,731)  (2,731)
                     
Balance, March 31, 2020  1,819,981  $2  $100,670  $(98,598) $2,074 

  

See accompanying notes to financial statements.

 


SENESTECH, INC.

SENESTECH, INC.
CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

  For the Nine Months 
  Ended September 30, 
  2017  2016 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $(9,975) $(7,174)
Adjustments to reconcile net loss to net cash used in operating activities:        
Gain on investments held to maturity  (20)   
Amortization of discounts on investments held to maturity  11    
Depreciation and amortization  273   143 
Stock-based compensation  2,818   2,406 
Non-cash charge for settlement of dispute     300 
Amortization of debt discount     27 
Gain on remeasurement of common stock warrant liability  (65)  (51)
Loss on extinguishment of unsecured promissory note     171 
(Increase) decrease in current assets:        
Accounts receivable  3   (4)
Prepaid expenses  165   (17)
Inventory  (337)   
Deposits  (8)   
Increase (decrease) in current liabilities:        
Accounts payable  (176)  77 
Accrued contract cancellation settlement  (1,000)   
Accrued expenses  703   61 
Deferred rent  12   (4)
Deferred revenues     (175)
Net cash used in operating activities  (7,596)  (4,240)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of securities held to maturity  (2,940)   
Purchase of property and equipment  (885)  (54)
Net cash used in investing activities  (3,825)  (54)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from the issuance of series B convertible preferred stock     896 
Proceeds from the issuance of common stock     6,199 
Proceeds from the issuance of convertible notes payable     326 
Repayments of convertible notes payable     (810)
Proceeds from the issuance of notes payable  437    
Repayments of notes payable  (48)  (24)
Repayments of notes payable, related parties  (18)  (721)
Repayments of capital lease obligations  (77)  (16)
Payment of deferred offering costs     (801)
Proceeds from exercise of stock options and warrants     449 
Net cash provided by financing activities  294   5,498 
         
NET CHANGE IN CASH  (11,127)  1,204 
CASH AT BEGINNING OF PERIOD  11,826   141 
CASH AT END OF PERIOD $699  $1,345 
         
         
SUPPLEMENTAL INFORMATION:        
Interest paid $55  $23 
Income taxes paid $  $ 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Purchases of equipment under capital lease obligations $316  $157 
Original issue discount $  $147 
Debt discount on convertible notes $  $9 
Related party convertible note extinguished for settlement payable $  $404 
Contributed capital, debt forgiveness by related parties $  $2,003 
Issuance of series B convertible preferred stock in connection with conversion of convertible notes and $  $16 
Issuance of shares of common stock upon conversion of Series B convertible preferred stock $  $260 
Dividends $  $90 
  For the Three Months 
  Ended March 31, 
  2020  2019 
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $(2,317) $(2,364)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  77   111 
Stock-based compensation  151   252 
Gain on sale of equipment  (15)  - 
Loss on change in fair value of derivative  -   5 
(Increase) decrease in current assets:        
Accounts receivable - trade  4   (11)
Accounts receivable - other  123   - 
Other assets  9   - 
Prepaid expenses  (40)  (3)
Inventory  18   (74)
Deferred rent obligation  -   1 
Increase (decrease) in current liabilities:        
Accounts payable  474   99 
Accrued expenses  (355)  37 
Deferred rent  -   (1)
Net cash used in operating activities  (1,871)  (1,948)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Cash received on sale of property and equipment  40   - 
Purchase of property and equipment  -   (11)
Net cash provided by (used in) investing activities  40   (11)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from the issuance of common stock, net  1,435   - 
Repayments of notes payable  (14)  (32)
Repayments of finance lease obligations  (34)  (19)
Proceeds from the exercise of warrants  -   36 
Net cash provided by (used in) financing activities  1,387   (15)
         
NET CHANGE IN CASH  (444)  (1,974)
CASH AT BEGINNING OF PERIOD  1,936   4,920 
CASH AT END OF PERIOD $1,492  $2,946 
         
SUPPLEMENTAL INFORMATION:        
Interest paid $8  $13 
Income taxes paid $-  $- 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Forgiveness of accrual in warrant exercise $238     
Deemed dividend $414  $- 
Common stock issued on accrued bonus $-  $32 

 

See accompanying notes to financial statements.

 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1 - Organization and Description of Business

 

SenesTech, Inc. (the “Company”(referred to in this report as “SenesTech,” the “Company,” “we” or “us”) was formed in July 2004 and incorporated in the state of Nevada. The Company subsequently reincorporated in the state of Delaware in November 2015. The Company has itsOur corporate headquarters is in Flagstaff,Phoenix, Arizona.

The Company has We have developed and are seeking to commercialize a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control. The Company believes that its innovative non-lethal approach, targeting reproduction,

Although there are myriad tools available to control rat populations, most rely on some form of lethal method to achieve effectiveness. Each of these solutions is more humane, less harmfulinherently limited by rat species’ resilience and survival mechanisms as well as their extraordinary rate of reproduction. ContraPest®, our initial product, is unique in the pest control industry in attacking the reproductive systems of both male and female rats, resulting in a sustained reduction of the rat population.

Rats have plagued humanity throughout history. They pose significant threats to the environment,health and more effective in providing a sustainablefood security of many communities. In addition, rodents cause significant product loss and damage through consumption and contamination. Rats also cause significant damage to critical infrastructure by burrowing beneath foundations and gnawing on electrical wiring, insulation, fire proofing systems, electronics and computer equipment.

The most prevalent solution to pestrat infestations than traditional lethalis the use of increasingly powerful rodenticides. Although these solutions provide short term results, there are growing concerns about secondary exposure and bioaccumulation of rodenticides in the environment, as well as concerns about rodenticides that have no antidotes. The pest management methods. Itsindustry and Pest Management Professionals (PMPs) are being asked for new solutions that are both effective and less toxic. Our goal is to provide customers with not only a solution to combat their most difficult rat problems, but also offer a non-lethal option to serve customers that are looking to decrease or remove the amount of rodenticide used in their pest control programs.

ContraPest is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest limits reproduction of male and female rats beginning with the first fertility control product candidate,breeding cycle following consumption. ContraPest is being marketed for use in controlling Norway and roof rat populations.

SenesTech began the rat population. The innovative compound is consumed by rats and leaves them non-reproductive without other observable side effects. The U.S.registration process with the United States Environmental Protection Agency (“EPA”) granted registration approval(EPA) for ContraPest effectiveon August 23, 2015. On August 2, 2016. The Company plans2016, the EPA granted an unconditional registration for ContraPest as a Restricted Use Product (RUP), due to the need for applicator expertise for deployment. On October 18, 2018, the EPA approved the removal of the RUP designation. We believe ContraPest is the first and only non-lethal, fertility control product approved by the EPA for the management of rodent populations.

In addition to the EPA registration of ContraPest in the United States, ContraPest must obtain registration from the various state regulatory agencies prior to selling in each state. We have received registration for ContraPest in all 50 states and the District of Columbia, 47 of which have approved the removal of the RUP designation.

We expect to continue to commercializepursue regulatory approvals and distributeamendments to the existing U.S. registration for ContraPest, by leveraging new and existing third-party relationshipsif ContraPest begins to generate sufficient revenue, regulatory approvals for additional jurisdictions beyond the United States. The Company also continues to research and develop enhancements to ContraPest that align with manufacturing, marketingour target verticals and distribution partnersother potential fertility control options for additional species.

Reverse Stock Split

On February 4, 2020, we amended our amended and restated certificate of incorporation to effect a 1-for-20 reverse split of our issued and outstanding shares of our common stock. The accompanying condensed financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, preferred stock conversions to common stock and per share amounts contained in our condensed financial statements have been retrospectively adjusted.

Our financial statements as of March 31, 2020 and 2019 have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm included in its opinion for the years ended December 31, 2019 and 2018 an explanatory paragraph referring to our net loss from operations and net capital deficiency and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available. If we encounter continued issues or delays in the U.S.commercialization of ContraPest, our prior losses and internationally.expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through additional financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Potential Note 1 - Organization and Description of Business – (continued)

Need for Additional Capital

 

InSince our inception, we have sustained significant operating losses in the course of itsour research and development and commercialization activities the Company has sustained operating losses since its inception and expectsexpect such losses to continue for the near future. The Company’sWe have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock. See “Description of Capital Stock” elsewhere in this filing for a description of our public equity sales.

We have also raised capital through debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through March 31, 2020, we had received net proceeds of $68.9 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.6 million in net product sales. At March 31, 2020, we had an accumulated deficit of $98.6 million and cash and cash equivalents of $1.5 million.

Our ultimate success depends upon the outcome of a combination of factors, including: (i) the success of its research and development; (ii) ongoing regulatory approval andsuccessful commercialization of ContraPest and its othermaintaining and obtaining regulatory approvals of our products and product candidates; (iii)(ii) market acceptance, and commercial viability and profitability of ContraPest and other products if the Company obtains the necessary regulatory approvals; (iv)products; (iii) the ability to market itsour products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) theour ability to retain and attract key personnel to develop, operate and grow itsour business; and (vi) the timely and successful completion ofour ability to meet our working capital needs.

We will need additional financing. The Company has funded its operations to date through the sale of convertible preferred stock and common stock, including an initial public offering of 1,875,000 shares of its common stock on December 8, 2016, debt financing, consisting primarily of convertible notes and, to a lesser extent, payments received in connection with research grants and licensing fees. As of September 30, 2017, the Company had cash and cash equivalents and highly liquid investments of $3,648. However, the Company is likely to require additional capitalfunding in order to continue to fund its operating lossesour operations and researchachieve profitability and development activities by issuingbecome cash flow positive and will continue to seek additional debt and equity instruments until such time as the Company is profitable.financing. If such equity or debt financing is not available at adequate levels the Company willor on acceptable terms, we may need to reevaluate its plans.delay, limit or terminate commercialization and development efforts or discontinue operations.

 

All amounts shown in these financial statements are in thousands, except percentages and per share and share amounts. Per share and share amounts reflect post-reverse split values.

Basis of Presentation

 

The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2017,March 31, 2020, the Company’s operating results for the three and nine months ended September 30, 2017March 31, 2020 and 2016,2019, and the Company’s cash flows for the ninethree months ended September 30, 2017March 31, 2020 and 2016.2019. The accompanying financial information as of December 31, 20162019 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 2016.

2019, filed with the SEC on March 17, 2020 and April 21, 2020, respectively. All amounts shown in these financial statements and accompanying notes are in thousands, except percentages and per share and share amounts.

 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”)GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform to the current periodyear presentation. These reclassifications had no impact on net earnings, financial position or cash flows.

 

Deferred Offering Costs

Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Company’s initial public offering on December 8, 2016. Deferred offering costs of $2,234 were offset against the proceeds received from the initial public offering in December 2016.There were no deferred offering costs at September 30, 2017.

Cash and Cash Equivalents

The Company considers money market fund investments to be cash equivalents. The Company had cash equivalents of $70 and $-0- at September 30, 2017 and December 31, 2016, respectively, included in cash as reported.

Investments in Securities Held to Maturity

The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds.Accounts Receivable-Trade

 

Accounts Receivable

Accounts receivablereceivable-trade consist primarily of trade receivables.receivables from customers. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $3 and $-0- as of September 30, 2017$123 at March 31, 2020 and December 31, 2016,2019, respectively.

 

Accounts Receivable-Other

Accounts receivable-other at March 31, 2020 was $0. Accounts receivable-other at December 31, 2019 consisted primarily of receivables related to insurance reimbursements due the Company.

Inventories

 

Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials, work in progress and finished goods. AsRaw materials are stocked to reduce the risk of September 30, 2017 and December 31, 2016, the Company had inventoriesimpact on manufacturing for potential supply interruptions due to COVID-19 or long lead times on certain ingredients.

Components of $394 and $57, respectively.inventory are:

 

  March 31,  December 31, 
  2020  2019 
Raw materials $1,024  $1,035 
Work in progress  -   - 
Finished goods  142   149 
  Total inventory  1,166   1,184 
Less:        
Reserve for obsolete  (4)  (4)
Total net inventory $1,162  $1,180 

 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies – (continued)

 

Prepaid Expenses

 

Prepaid expenses consist primarily of payments made for director and officer insurance, director compensation, rent, legal and inventory purchase deposits and seminar fees to be expensed in the current year.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Equipment held under capitalfinance leases are stated at the present value of minimum lease payments less accumulated amortization.

 

Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capitalfinance leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs repair and maintenance costs on its major equipment. Repair and maintenance costsequipment, which are expensed as incurred.

 

Impairment of Long-Lived Assets

 

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- partythird-party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception.

 


Revenue RecognitionSENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

TheNote 2 - Summary of Significant Accounting Policies – (continued)

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 —Revenue from Contracts with Customers(“ASC 606”).Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies whenby applying the following steps: (1) persuasive evidence of an arrangement exists;identify the contract with a customer; (2) identify the performance of service has been renderedobligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to a customer or delivery has occurred; (3)each performance obligation in the amount of fee to be paid by a customercontract; and (5) recognize revenue when each performance obligation is fixed and determinable; and (4) the collectability of the fee is reasonably assured.

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)satisfied.

 

The Company has generatedrecognizes revenue fromwhen product is shipped at a license agreement with a strategic partner, pursuant to which the Company had granted to such partner the exclusive right to manufacture and distribute its product, ContraPest, once the required regulatory approvals were received. This licensing agreement was subsequently terminatedfixed selling price on January 23, 2017. Thepayment terms of the licensing agreement contained multiple elements or deliverables, as discussed below. Management evaluates whether the arrangement involving the multiple deliverables contains more than one unit of accounting. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances of the arrangement.

The Company determined that the license granted pursuant30 to the license agreement did not have stand-alone value and, therefore, the nonrefundable, upfront license fee payments received by the Company are recognized on a straight-line basis over the estimated related performance period (i.e.120 days from the effective date of the agreement through the estimated completion date of the Company’s substantive performance obligations).

In accordance with the terms of the license agreement, the Company was also to receive a future fixed amount of contingent milestone payments (i.e. post-regulatory approval license fees) and contingent sales-based royalties to be received upon the achievement of certain milestone events. The milestone events under the agreement include regulatory approval, patent issuance or alternative intellectual property coverage, and sales-based events. The Company did not earn or receive any of the potential contingent milestone payments, as the milestone events to receive such post-approval license fees and sales-based royalties were not achieved. The Company recognizes revenue that is contingent upon the achievement of a substantive milestone event in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to the Company for such milestone has all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (ii) the event can only be achieved based in whole or part on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (iii) if achieved, the event would result in additional payments being due to the Company. As the potential contingent consideration was to be received only upon the achievement of milestone events that are considered substantive, the Company would only recognize such revenue in the period the milestone is achieved and the milestone payments became due and collectible. In addition, the Company accounts for sales-based royalties as revenue upon achievement of certain sales milestones. 

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the balance sheet. Amounts expected to be recognized as revenue in the next twelve months following the balance sheet date are classified as a current liability.

invoicing. The Company recognizes other revenue earned from pilot studies upon the performance of specific services under the respective service contract.

 

For the nine months ended September 30, 2017, theThe Company generated net revenuesderives revenue primarily from commercial sales of $34.products.

 

Research and Development

 

Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, and costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs.costs, and manufacturing costs associated with process improvement. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment.

 

SENESTECH, INC.Stock-based Compensation

 

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

Stock-based Compensation

Employee stock-basedStock based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model.model for stock options and grant date market value for restricted stock units. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved.

 


For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurementSENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 2 - Summary of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest.Significant Accounting Policies – (continued)

 

The stock-based compensation expense recorded for the three and nine months ended September 30, 2017March 31, 2020 and 20162019, is as follows:

 

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 2017  2016  2017  2016  Three Months Ended
March 31,
 
          2020  2019 
Research and development $85  $135  $269  $309  $3  $9 
General and administrative  861   798   2,549   2,097 
Selling, general and administrative  148   243 
Total stock-based compensation expense $946  $933  $2,818  $2,406  $151  $252 

 

See Note 11 for additional discussion on stock-based compensation.

Income Taxes

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.

 

10 

SENESTECH, INC.The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements.

 

The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of March 31, 2020 or December 31, 2019 and as such, no interest or penalties were recorded in income tax expense.


SENESTECH, INC. 

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies – (continued)

 

Comprehensive Loss

 

Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.

 

Loss Per Share Attributable to Common Stockholders

 

Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, the Series A convertible preferred stock (prior to its conversion into common stock), Series B convertible preferred stock (prior to its conversion into common stock), convertible promissory notes (prior to their conversion), common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2017March 31, 2020 and 2016.2019. Therefore, basic and diluted loss per share attributable to common stockholders wasare the same for all periodseach period presented.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares):

 

 September 30,  March 31, 
 2017  2016  2020  2019 
Series A convertible preferred stock     400,000 
Series B convertible preferred stock     483,609 
Common stock purchase warrants  829,285   750,185   812,963   321,590 
Restricted stock units  344,982    
Restricted stock unit  5,877   11,895 
Common stock options  1,558,800   1,321,300   136,239   81,499 
Total  2,733,067   2,955,094   955,079   414,984 

 

11 

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies – (continued)

 

In May 2017,Adoption of New Accounting Standards:

Effective January 1, 2019, the FASB issuedCompany adopted Accounting Standard UpdateStandards Updated (“ASU”)No. 2016-02, 2017-9,Compensation — Stock CompensationLeases (Topic 718): Scope of Modification Accounting842)  (“ASU2017-9”), which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718.Per (“ASU 2017-9, an entity should account for the effects of a modification unless all the following are met: (1) the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirements in Topic 718 apply regardless of whetherNo. 2016-02”).  Under ASU No. 2016-02, an entity is required to apply modification accounting underrecognize right-of-use lease assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements.  The Company elected the amendmentsoptional transition method provided by the FASB in ASU 2017-9.ASU 2017-9 is effective for public business entities for annual2018-11, Leases (Topic 842): Targeted Improvements, and interim periods in fiscal years beginning after December 15, 2017.Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for whichas a result, has not restated its condensed consolidated financial statements havefor prior periods presented. The Company has elected the practical expedients upon transition to retain the lease classification and initial direct costs for any leases that existed prior to adoption. The Company has also not yet been issued and (2)reassessed whether any contracts entered into prior to adoption are leases. The Company applied the new guidance to all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendmentsoperating leases within the scope of the standard that were in this ASU should be applied prospectively to an award modifiedeffect on January 1, 2019, or entered into after, the adoption date.  Comparative information for prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods.  The adoption ofASU 2017-9 isdid not expected to have a material impact on the Company’s financial statementsconsolidated statement of comprehensive income (loss).  However, the new standard established $87 of liabilities and corresponding right-of-use assets of $87 on the Company’s consolidated balance sheet for leases, primarily related to operating leases on rented office properties, that existed as of the January 1, 2019, adoption date. 

At March 31, 2020, the balance in Right to Use Asset-Long Term and Lease Liability-Long Term was $622 and ($624) respectively and at December 31, 2019, the balance in Right to Use Asset-Long Term and Lease Liability-Long Term was $699 and ($694) respectively.

The Company’s leases primarily relate to operating leases of rented office properties.  For contracts entered into on or after January 1, 2019, at the inception of a contract the Company assesses whether the contract is, or contains, a lease.  The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether the Company has the right to direct the use of the asset.  At inception of a lease, the Company allocates the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

For leases with terms greater than 12 months, the Company records the related disclosures.asset and obligation at the present value of lease payments over the term.  The right-of-use lease asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.


SENESTECH, INC. 

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 2 -Summary of Significant Accounting Policies – (continued)

The right-of-use lease asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred.  All right-of-use lease assets are reviewed for impairment.  The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s secured incremental borrowing rate for the same term as the underlying lease.

The Company identified and assessed the following significant assumptions in recognizing the right-of-use lease assets and corresponding liabilities.

Expected lease term – The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods.  When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

 

Incremental borrowing rate – As the Company’s leases do not provide an implicit rate, the Company obtained the incremental borrowing rate (“IBR”) based on the remaining term of each lease.  The IBR is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.  

The Company has elected not to recognize right-of-use lease assets and lease liabilities for short-term leases that have a term of 12 months or less.

The Company reports right-of-use lease assets within non-current assets in its consolidated balance sheet.  The Company reports the lease liabilities within long-term liabilities in its consolidated balance sheet.

See Note 12, Commitments and Contingencies, for future minimum lease payments and maturities.

In August 2016,2018, the FASB issued ASU No. 2016-15,Statement of Cash Flows (Topic230): Classification of Certain Cash Receipts and Cash Payments.authoritative guidance intended to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The amendments in this ASU provide guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest ratealso requires presentation of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds fromcapitalized implementation costs in the settlementstatement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interestsfinancial position and in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of ASU No. 2016-15 is not expected to have a material impact on the Company’s financial statements or related disclosures.

In March 2016, the FASB issued ASU No. 2016-09,Improvements to Employee Share-Based Payment Accounting(“ASU 2016-09”). This standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09flows in the same line item that a prepayment for the fees of the associated hosting arrangement would be presented, and the expense related to the capitalized implementation costs to be presented in the same line item in the statement of operations as the fees associated with the hosting element (service) of the arrangement. This guidance is effective for annual periods beginning after December 15, 2016 and2019, including interim periods within those annual periods, for public business entities. The method ofwith early adoption is dependent on the specific aspect of accounting addressed in this new guidance. Early adoption was permitted in any interim or annual period. ASU 2016-09 was adopted bypermitted. . Effective January 1, 2020, the Company and did not have a material impact on the Company’s financial statements or related disclosures.

In February 2016, the FASB issued ASU No. 2016-02,Leases(“ASU 2016-02”). This standard amends various aspects of existing accounting guidance for leases, including the recognition of a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. This standard also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years for public business entities. Early adoption is permitted and the new standard must be adopted using a modified retrospective approach, and provides for certain practical expedients. The Company is evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.


In January 2016, the FASB issued ASU No. 2016-01,Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities(“ASU 2016-01”). This standard affects the accounting for equity instruments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. ASU 2016-01 is effective in the first quarter of 2019. The Company is evaluating the impact of the adoption of ASU 2016-01 on its financial statements and related disclosures.

In November 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2015-17,Balance Sheet Classification of Deferred Taxes, which eliminates the guidance in Topic 740, Income Taxes, that required an entityand determined there was no applicability to separate deferred tax assets and liabilities between current and noncurrent amounts in a classified balance sheet. The amendments require that all deferred tax assets and liabilities of the same jurisdiction or a tax filing group, as well as any related valuation allowance, be offset and presented as a single noncurrent amount in a classified balance sheet. The standard became effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, and may be applied on either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company has adopted this standard retrospectively for all periods presented. The adoption of this standard did not have a material impact on the Company’s financial statements.

The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements.

The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of September 30, 2017 or December 31, 2016at this time and as such, no interest or penalties were recorded in income tax expense.

In August 2014, the FASB issued ASU No. 2014-15,Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern(“ASU 2014-15”). This standard requires management to perform an evaluation in each interim and annual reporting period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year of the date the financial statements are issued. If such conditions or events exist, ASU 2014-14 also requires certain disclosures of management’s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will alleviate the substantial doubt. ASU No. 2014- 15 is effective for the annual period ending after December 15, 2016 and for annual and interim periods thereafter. Early adoption was permitted for annual or interim reporting periods for which the financial statements have not been previously issued. ASU 2014-15 was adopted by the Company and did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

In May 2014 the FASB issued ASU No. 2014-09,Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Adoption of the new standard is effective for reporting periods beginning after December 15, 2017. We plan to use the modified retrospective method of adoption and will adopt the standard as of January 1, 2018, the beginning of our next fiscal year.. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, we do not expect adoption will have a materialno impact on our financial position, results of operations, or cash flows. Related disclosures will be expanded

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in line with the requirements of the standard. We will continuecurrent year that we believe have a significant impact, or potential significant impact, to our evaluation until our adoption of the new standard.unaudited condensed consolidated interim financial statements.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 3 - Fair Value Measurements

 

The carrying amountsCompany issued common stock warrants to purchase shares of certaincommon stock in June of 2015 (see Note 11 — Stock-based Compensation for more details) that contain a cash settlement provision resulting in a common stock warrant liability that is revalued at the Company’s financial instruments, including cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. Assets and liabilities recordedend of each reporting period.

We value these warrant derivatives at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values.value. The accounting guidance for fair value, providesamong other things, establishes a consistent framework for measuring fair value and requires certain disclosures about howexpands disclosure for each major asset and liability category measured at fair value is determined.on either a recurring or nonrecurring basis. Fair value is defined as the price that would be received upon the sale ofto sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurementreporting date. The accounting guidance also establishesframework for measuring fair value consists of a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:

 

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

 

Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

 

Level 3—Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

 

An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:

A.

Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

B.Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

C.

Income approach: Techniques to convert future amounts to a single present amount based upon market expectations, including present value techniques, option-pricing and excess earnings models.

The Company’s cash equivalents, which include money market funds,common stock warrant liabilities are classified as Level 13 because they are valued using quoted market prices. The Company’s marketable securities consist of held to maturity securities and are generally classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data.

In certain cases where there is limited activity or less transparency around the inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of common stock warrant liability.valuation.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 3 - Fair Value Measurements – (continued)

 

Items Measured at Fair Value on a Recurring Basis

 

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

  September 30, 2017 
  Level 1  Level 2  Level 3  Total 
Financial Assets:                
Money market funds $70  $  $  $70 
Corporate fixed income debt securities     2,949      2,949 
Total $70  $2,949  $  $3,019 
Financial Liabilities:                
Common stock warrant liability(1) $  $  $4  $4 
Total $  $  $4  $4 
March 31, 2020
Level 1Level 2Level 3Total
Financial Liabilities:
Common stock warrant liability$-$-$-$-
Total$-$-$-$-

 

  December 31, 2016 
  Level 1  Level 2  Level 3  Total 
Financial Assets:                
None $  $  $  $ 
                 
Financial Liabilities:                
Common stock warrant liability(1) $  $  $69  $69 
Total $  $  $69  $69 

(1) The change in the fair value of the common stock warrant and convertible notes payable for the three and nine months ended September 30, 2017 was recorded as a decrease to other income (expense) and interest expense of $30 and $69, respectively, in the statements of operations and comprehensive loss.

  December 31, 2019 
  Level 1  Level 2  Level 3  Total 
Financial Assets:            
Money market funds $-  $-  $-  $- 
                 
Corporate fixed income debt securities  -   -   -   - 
                 
Total $3  $-  $-  $- 
Financial Liabilities:                
Common stock warrant liability $-  $-  $-  $- 
Total $-  $-  $-  $- 

  

Financial Instruments Not Carried at Fair Value

 

The carrying amounts of the Company’s financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of the convertible notes and other notes, not recorded at fair value, are recorded at cost or amortized cost which was deemed to estimate fair value.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 4 - Investment in Securities Held to MaturityCredit Risk

As of September 30, 2017, investment in securities held to maturity primarily consisted of corporate fixed income securities and commercial paper. The Company did not have investments prior to the first quarter of 2017. The Company classifies all investments as held to maturity as these investments are short term, highly liquid investments which we intend to hold to maturity. Held to maturity securities are recorded at cost and gains and losses are only recognized as the sale or redemption of the securities is realized. Realized gains and losses are included in non-operating other income (expense) on the condensed statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three and nine months ended September 30, 2017, the Company had a minimal amount of net realized gain (loss) on investments recorded. Interest and dividends on investments held to maturity are included in interest and other income, net, in the condensed statements of operations.

 

The followingCompany is potentially subject to concentrations of credit risk in its accounts receivable. Credit risk with respect to receivables is limited due to the number of companies comprising the Company’s customer base, however the Company did identify a summarypotentially uncollectable account and at March 31, 2020 and December 31, 2019 maintained a reserve for this receivable balance of held$123. The Company does not require collateral or other securities to maturity securities at September 30, 2017:support its accounts receivable.

    September 30, 2017 
  Contractual
Maturity (in months)
 Cost  Gross Unrealized
Gains
  Gross Unrealized
Losses
  Fair Market
Value
 
Mutual funds   $  $  $  $ 
Corporate fixed income securities Less than 12 months  2,746   3      2,749 
Commercial paper Less than 12 months  200         200 
Total investments   $2,946  $3  $  $2,949 

 

Note 5 - Prepaid Expenses

 

Prepaid expenses consist of the following:

 

  September 30,
2017
  December 31,
2016
 
Director compensation $  $215 
Director, officer and other insurance  95   70 
Legal retainer  25   25 
Rent  17   17 
Inventory Purchase Deposits  20    
Engineering, software licenses and other  15   10 
Total prepaid expenses $172  $337 

16

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

  March 31,  December 31, 
  2020  2019 
Director compensation $-  $9 
Director and officer insurance  123   115 
NASDAQ fees  43   - 
Legal retainer  25   25 
Marketing programs and conferences  73   80 
Professional services retainer  8   8 
Rent  20   11 
Equipment service deposits  -   1 
Engineering, software licenses and other  5   8 
Total prepaid expenses $297  $257 

 

Note 6 - Property and Equipment

 

Property and equipment, net consist of the following:

 

   March 31, December 31, 
 Useful
Life
 September 30,
2017
  December 31,
2016
  Useful Life 2020  2019 
Research and development equipment 5 years $1,335  $989  5 years $1,470  $1,585 
Office and computer equipment 3 years  672   235  3 years  733   753 
Autos 5 years  54   54 
Furniture and fixtures 7 years  34   17  7 years  41   41 
Autos/Trucks 5 years  306    
Leasehold improvements *  283   189  *  283   283 
    2,630   1,430     2,581   2,716 
Less accumulated depreciation and amortization    1,071   799     (1,945)  (1,978)
Total   $1,559  $631    $636  $738 

* Shorter of lease term or estimated useful life

 

In the three months ended March 31, 2020, the Company received net proceeds of $40 in the sale of research and development equipment and office and computer equipment, resulting in a gain on the sale of these assets of $15.

Depreciation and amortization expense was approximately $118$77 and $49$111 for the three months ended September 30, 2017March 31, 2020 and 2016, respectively, and $272 and $143 for the nine months ended September 30, 2017 and 2016,2019, respectively.

 

Note 7 - Accrued Expenses

 

Accrued expenses consist of the following:

 

  September 30,
2017
  December 31,
2016
 
Compensation and related benefits $705  $82 
Accrued litigation  269   286 
Research project agreement  100    
Other     3 
Total accrued expenses $1,074  $371 

Note 8 - Accrued Contract Cancellation Settlement

The accrued contract cancellation settlement of $1,000 was the result of the Company entering into a settlement agreement with Neogen Corporation in which Neogen and the Company agreed to (a) terminate the existing Exclusive License Agreement between the Company and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or the Company having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”); and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. Under the terms of the agreement, the Company agreed to make a one-time payment in the amount of $1,000 in settlement of all claims and termination of all existing contracts between the parties. This payment was made in January, 2017. See Note 15 for further details.

  March 31,  December 31, 
  2020  2019 
Compensation and related benefits $578  $935 
Accrued Litigation  -   238 
Board Compensation  9   17 
Personal property and franchise tax  10   2 
Other  3   1 
Total accrued expenses $600  $1,193 

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

Note 9 - Borrowings

A summary of the Company’s borrowings, including capital lease obligations, is as follows:

  September 30,
2017
  December 31,
2016
 
Short-term debt:        
Current portion of long-term debt  174   45 
Total short-term debt $174  $45 
Long-term debt:        
Capital lease obligations $290  $51 
Other unsecured promissory notes  521   132 
Total  811   183 
Less: current portion of long-term debt  (174)  (45)
Total long-term debt $637  $138 

Capital Lease Obligations

Capital lease obligations are for computer and lab equipment leased through Great American, Thermo Fisher, Navitas and ENGS. These capital leases expire at various dates through June 2022. Also included in the table above are three notes payable to Direct Capital and one to M2 Financing for the financing of fixed assets.

Note 10 - Notes Payable, Related Parties

A summary of the Company’s notes payable, related parties is as follows:

  September 30,
2017
  December 31,
2016
 
Unsecured promissory note, interest rate of 4.25% and 8% per annum $18  $36 
Less: current portion of notes payable, related parties  18   30 
Total notes payable, long-term, related parties $  $6 

In April 2013, the Company and a previous employee entered into an agreement to settle all outstanding obligations consisting of a promissory note of $40, dated March 2009, and deferred salaries amounting to $72. The note and salary obligation continue to bear interest at 8% and 4.25%, respectively. The note requires monthly payments of $1 and matures in April 2018. The deferred salary obligation requires monthly payments of $1 and matures in May 2018.

Amounts outstanding on these obligations were $18 and $36 at September 30, 2017 and December 31, 2016, respectively.

Interest expense on the notes payable, related parties, was $-0- and $1 for the three months and nine months ended September 30, 2017 and $56 for the year ended December 31, 2016 respectively.


TECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 8 - Borrowings

A summary of the Company’s borrowings, including finance lease obligations, is as follows:

  March 31,  December 31, 
 2020  2019 
Short-term debt:      
Current portion of long-term debt  116   123 
Total short-term debt $116  $123 
Long-term debt:        
Finance lease obligations $120  $155 
Other promissory notes  92   105 
Total  212   260 
Less: current portion of long-term debt  (116)  (123)
Total long-term debt $96  $137 

Finance Lease Obligations 

Finance lease obligations at March 31, 2020 are for computer and lab equipment leased through GreatAmerica Financial Services, Navitas Credit Corp. and ENGS Commercial Finance Co. These finance leases expire at various dates through April 2022 and carry interest rates ranging from 7.3% to 18.3%.

Other Promissory Notes

Also included in the table above are notes payable to Direct Capital, M2 Financing and Fidelity Capital, all for the financing of fixed assets. These notes expire at various dates through June 2022 and carry interest rates ranging from 13.1% to 13.3%.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 119 - Common Stock Warrants and Common Stock Warrant Liability

 

The table summarizes the common stock warrant activity as of September 30, 2017March 31, 2020 as follows:

 

  Number          
  of  Date     Exercise 
Common  Stock Warrants Warrants  Issued  Term  Price 
Outstanding at December 31, 2015  610,487            
Initial Public Offering Underwriter  187,500  December 2016   5 years  $9.60 
Marketing and Development Services  100,000  February 2016   5 years(1)  $7.50 
Other Advisory Services  40,000  August 2016   3 years(1)  $7.50 
Promissory Notes  9,031  March 2016   3 years(1)  $7.50 
Warrants issued  336,531            
Warrants exercised  (117,733)           
Outstanding at December 31, 2016  829,285            
Warrants issued              
Warrants exercised              
Outstanding at September 30, 2017  829,285            
       Balance           Balance           Balance 
Issue Date Warrant Type 

Term
Date

 Exercise
Price
  December 31,
2018
  Issued  Exercised  Expired  December  31,
2019
  Issued  Exercised  Expired  March 31,
2020
 
2016 and prior Various Various-2020/2021  Various   17,059   -   -   -   17,059   -   (9,375)  -   7,684 
  Common  Stock Offering                                          
November 21, 2017 Warrants November 21, 2022 $2.1122(1)  159,092   -   (15,591)  -   143,501   -       -   143,501 
November 21, 2017 Dealer Manager Warrants November 21, 2022 $30.00   47,250   -   -   -   47,250   -   (47,250)  -   - 
June 20, 2018 Warrant Reissue December 20, 2023 $36.40   56,696   -   -   -   56,696   -   -   -   56,696 
August 13, 2018 Rights Offering Warrants July 25, 2023 $23.00   267,853   -   (64,910)  -   202,943   -   -   -   202,943 
August 13, 2018 Dealer Manager Warrants August 13, 2023 $34.50   13,393   -   -   -   13,393   -   -   -   13,393 
July 16, 2019 Dealer Manager Warrants July 11, 2024 $33.75   -   8,334   -   -   8,334   -   -   -   8,334 
January 28, 2020 Registered Direct Offering July 28, 2025 $9.00   -   -   -   -   -   177,500   -   -   177,500 
January 28, 2020 Dealer Manager Warrants July 28, 2025 $10.00   -   -   -   -   -   13,312   -   -   13,312 
March 6, 2020 Registered Direct Offering September 8, 2025 $2.88   -   -   -   -   -   176,372   -   -   176,372 
March 6, 2020 Dealer Manager Warrants March 4, 2025 $3.76   -   -   -   -   -   13,228   -   -   13,228 
                                             
           561,343               489,176               812,963 

 

(1)ThePursuant to antidilution price adjustment protection contained within these warrants, also terminate, if not exercised by the earlierinitial exercise price of (i) Decemberthese warrants was $30.00 per share, which adjusted downward to $29.40 on July 24, 2018, the record date of the Right’s Offering, downward to $19.00 per share on August 13, 2018, or the second anniversarydate of the closingRights Offering, downward to $7.13 per share on January 28, 2020, the date of an initial public offeringa Registered Direct Offering and downward to $2.1122 per share on March 6, 2020, the date of common stock; or (ii) a liquidation, dissolution or winding up of the Company.Registered Direct Offering.

 

Promissory Notes; Common StockOutstanding Warrants

 

In conjunction with the issuance byAs of March 31, 2020, we had 812,963 shares of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of $12.58 per share.

On November 21, 2017, the Company issued a total of certain promissory notes, the Company issued232,875 detachable common stock warrants (“Warrants”) to purchase an aggregate 270,400issued with the second public offering of 293,000 shares of its common stock with an exercise price of $7.50at $20.00 per share. The Warrants werecommon stock warrant is exercisable until the earlier of (i) 5five years from the date of grant; (ii) December 13, 2018, or the second anniversarygrant. The common shares of the closing of our initial public offering;Company’s stock and (iii)detachable warrants exist independently as separate securities. As such, the closing of liquidation, dissolution or winding up ofCompany estimated the Company.

The Warrants have a net share settlement (cashless exercise) provision. With this provision the holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the common stock warrants, exercisable at $30.00 per share, to be $661 using a lattice model based on the timefollowing significant inputs: common stock price of $20.00; comparable company volatility of 73.8%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.87. The initial exercise price of these warrants was $30.00 per share, which adjusted downward to $29.40 on July 24, 2018, the record date of the warrant after deductionRight’s Offering and downward to $19.00 per share on August 13, 2018, the date of the aggregate exercise price. However, the Warrants would be exercised automatically in fullRights Offering, pursuant to the netantidilution price adjustment protection contained within these warrants. The exercise provision, without any further action on behalfprice of the holder,warrants was adjusted downward to $7.13 on January 28, 2020 in connection with a private placement of common stock. Per guidance of ASC 260, the Company recorded a deemed dividend of $285 on the 143,501 unexercised warrants that contained this antidilution price adjustment protection provision and was calculated as the difference between the fair value of the warrants immediately prior to downward exercise price adjustment and immediately after the timeadjustment using a Black Scholes model based on the Warrants would otherwise terminate.following significant inputs: On January 28, 2020, common stock price of $7.90; comparable company volatility of 73.8%; remaining term 2.82 years; dividend yield of 0% and risk-free interest rate of 1.45%.

 

The Warrants are considered freestanding instrumentsexercise price of the warrants was adjusted downward to $2.1122 on March 4, 2020 in connection with a private placement of common stock. Per guidance of ASC 260, the Company recorded a deemed dividend of $129 on the 143,501 unexercised warrants that contained this antidilution price adjustment protection provision and was calculated as (i) they were transferred together with the notes issued but exist independently asdifference between the fair value of the warrants immediately prior to downward exercise price adjustment and immediately after the adjustment using a separate security; (ii) they may be exercised separately fromBlack Scholes model based on the notes;following significant inputs: On March 4, 2020, common stock price of $2.88; comparable company volatility of 74.5%; remaining term 2.71 years; dividend yield of 0% and (iii) they are exercisable for a specific period (term) and do not impact the notes if and when exercised. 

risk-free interest rate of 0.68%.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

  

Note 119 -Common Stock Warrants and Common Stock Warrant Liability – (continued)

 

On June 20, 2018, the Company entered into an agreement with a holder of 56,696 of the November 2017 warrants to exercise its original warrant representing 56,696 shares of common stock for cash at the $30.00 exercise price for gross proceeds of $1.7 million and the Company issued to holder a new warrant to purchase 56,696 shares of common stock at an exercise price of $36.40 per share. The new warrant did not contain the antidilution price adjustment protection that was contained within the exercised warrants. In June 2018, the Company recorded stock compensation expense of $1.7 million representing the fair value of the of 56,696 inducement warrants issued. The Company estimated the fair value of the Warrantscommon stock warrants, exercisable at issuance$36.40 per share, to be $1.7 million using a Monte Carlo option pricingBlack Scholes model based on the following significant inputs: common stock price of $7.50 to $7.575;$42.20; comparable company volatility of 58.0%72.6%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.8%. Also, in June 2018, an additional 17,088 of the November 8, 2017 warrants that were in the money at the time of exercise, were exercised for gross proceeds of $513.

On August 13, 2018, in connection with a Rights Offering of 267,853 shares of its common stock, the Company issued 267,853 warrants to 76.7%; risk- free ratespurchase shares of 1.31% to 1.76%; and the probabilityits common stock at an exercise price of an equity event occurring.$23.00 per share. The Company reflectedestimated the amounts recorded forfair value of the Warrants issued within stockholders’ deficit, as additional paid-in-capital. Although the Warrants are a derivative that can be net share settled, the Warrants are considered indexed to the Company’s common stock warrants, exercisable at $23.00 per share, to be $3.6 million using a Monte Carlo model based on the following significant inputs: common stock price of $18.80; comparable company volatility of 159.0%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.77%.

In connection with the closing of the Rights Offering, the Company hasissued a warrant to purchase 13,393 shares of common stock to Maxim Partners LLC, an affiliate of the abilitydealer-manager of the Rights Offering. The Company estimated the fair value of the common stock warrants, exercisable at $34.50 per share, to settlebe $169 using a using a Monte Carlo model based on the warrant contract infollowing significant inputs: common sharesstock price of $18.80; comparable company volatility of 159.0%; remaining term 5 years; dividend yield of 0% and met the conditions within the contract to classify the Warrants as an equity instrument.risk-free interest rate of 2.77%.

 

Common Stock Warrant Issued for Marketing and Development Servicesto Underwriter of Common Stock Offering

In February 2016,July 2019, the Company issued to a stockholderH.C. Wainwright & Co., as placement agent, a warrant to purchase 100,0008,334 shares of common stock at an exercise price of $7.50$33.75 per share as consideration for providing marketing and development services in Southeast Asia.connection with a common stock offering in July 2019. The warrant was fully vested and exercisable on the date of grant. The common stock warrant has the similar features as the Warrants discussed above, except it is exercisable until the earlier of (i) five years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrant to be $431 on the date of grant using a Black- Scholes option pricing model based on the following significant inputs:common stock price of $7.57; comparable company volatility of 77.8%; remaining term 3.75 years; dividend yield of 0% and risk-free rate of 2.09%. The Company recorded the fair value of the warrant as stock-based compensation expense within general and administrative expense on the date of grant.

March 2016 Promissory Notes Common Stock Warrants

In March 2016, the Company issued certain unsecured notes with common stock warrants to purchase an aggregate of 9,032 shares of common stock at an exercise price of $7.50 per share. The common stock warrants are exercisable until the earlier of (i) three years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrants on the date of grant using a Monte Carlo pricing model based on the following significant inputs: common stock price of $7.575; comparable company volatility 79.6%; and risk-free rate of 1.49%.

August 2016 Other Advisory Services

On August 16, 2016, the Company issued to each of two advisors warrants to purchase 20,000 shares of common stock at an exercise price of $7.50 per share as consideration for providing advisory services to the Company. The warrants were fully vested and exercisable on the date of grant until the earlier of (i) three years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company recorded the fair value of the warrants as stock-based compensation expense within general and administrative expense on the date of grant.

Common Stock Warrant Issued to Initial Public Offering Underwriter

In December 2016, the Company issued to the underwriter of its IPO a warrant to purchase 187,500 shares of common stock at an exercise price of $9.60 per share as consideration for providing services in connection with the Company’s initial public offering. The warrant was fully vested and exercisable on the date of grant.issuance. The common stock warrant is exercisable until five years from the date of grant. The Company estimated the fair value of the common stock warrantwarrants, exercisable at $33.75 per share, to be $939 on the date of grant$127 using a Black- Scholes option pricinglattice model based on the following significant inputs:inputs: common stock price of $8.00;$26.80; comparable company volatility of 82.1%133.3%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.92%2.07%.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 11 - Common Stock Warrants and Common Stock Warrant Liability – (continued)

 

University of Arizona Common Stock Warrant

 

In connection with the June 2015 amended and restated exclusive license agreement with the University of Arizona (“University”), the Company issued to the University a common stock warrant to purchase 15,000750 shares of common stock at an exercise price of $7.50$150.00 per share. The warrant was fully vested and exercisable on the date of grant, and expires, if not exercised, five years from the date of grant. In the event of a “terminating change” of the Company, as defined in the warrant agreement, the warrant holder would be paid in cash the aggregate fair market value of the underlying shares immediately prior to the consummation of the terminating change event. Due to the cash settlement provision, the derivative warrant liability was recorded at fair value and is revalued at the end of each reporting period. The changes in fair value are reported in other income (expense) in the statements of operations and comprehensive loss. The estimated fair value of the derivative warrant liability was $53 at the date of grant.

 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 9 -Common Stock Warrants and Common Stock Warrant Liability – (continued)

The estimated fair value of the derivative warrant liability was $4$0 at September 30, 2017.March 31, 2020. As this derivative warrant liability is revalued at the end of each reporting period, the fair values as determined at the date of grant and subsequent periods werewas based on the following significant inputs using a Monte Carlo option pricing model: common stock price of $7.91;$158.20; comparable company volatility of 77.7% of the underlying common stock; risk-free rates of 1.93%; and dividend yield of 0%; including the probability assessment of a terminating change event occurring. The change in fair value of the derivative warrant liability was $65$0 for the ninethree months ended September 30, 2017 andMarch 31, 2020. As such, no entry was recorded in other income (expense) in the accompanying statements of operations and comprehensive loss.

 

July 2015 Consulting Agreement Common Stock WarrantWarrants Issued in January and March 2020 Private Placements

 

In July 2015,January and March 2020, in separate private placements concurrent with registered direct offerings (collectively, the “2020 Registered Direct Offerings”) of shares of the Company’s common stock, the Company also issued a common stock warrantwarrants to purchase 121,227an aggregate of up to 353,872 shares of common stock withto certain institutional and accredited investors that participated in the 2020 Registered Direct Offerings. The warrants were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Terms used but not otherwise defined herein will have the meanings given them in the warrants, attached as Exhibit 4.1 to our Form 8-K filed on January 28, 2020, and our Form 8-K filed on March 6, 2020.

The warrants issued in January 2020 to purchase 177,500 shares of common stock have an exercise price of $7.50$9.00 per share, are exercisable after July 28, 2020 and will expire July 28, 2025. The warrants issued in March 2020 to purchase 176,372 shares of common stock have an exercise price of $2.88 per share, are immediately exercisable and will expire September 8, 2025.

For so long as consideration for servicesthe 2020 Warrants remain outstanding, the exercise price and number of shares of common stock issuable upon exercise of the warrants are subject to adjustment as follows: (a) upon payment of a stock dividend or other distribution on a class or series of shares common stock, not including shares issued under this warrant; (b) upon subdivision (by stock spilt, stock dividend, recapitalization, or otherwise) or combination (by reverse stock split or otherwise) of shares of common stock; or (c) upon the issuance of any shares of capital stock by reclassification of shares of the common stock.

In the event that the Company declares or makes any dividend or other distribution of its assets to holders of its common stock, each 2020 Warrant holder will be entitled to participate in such distribution to the same extent that such holder would have participated therein if the holder had held the number of shares of common stock acquirable upon exercise of the 2020 Warrant.

In the event of a consulting arrangement. TheFundamental Transaction, as described in the 2020 Warrants and generally including the sale, transfer or other disposition of all or substantially all of our properties or assets; our consolidation or merger with or into another person or reorganization; a recapitalization, reorganization or reclassification in which our common stock is converted into other securities, cash or property; or any acquisition of our outstanding common stock that results in any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, then the holders of the 2020 Warrants will be entitled to receive upon exercise of such warrants the kind and amount of securities, cash, assets or other property that the holders would have received had they exercised the 2020 Warrants immediately prior to such Fundamental Transaction. Subject to certain limitations, in the event of a Fundamental Transaction the 2020 Warrant holder may at its option require the Company or any Successor Entity to purchase such warrant was fully vested and exercisablefrom the holder by paying to the holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of the 2020 Warrant on the date of grant. Thisthe consummation of the Fundamental Transaction.

Any time that the Company grants, issues, or sells any securities pro rata to all of the record holders of the common stock (the “2020 Purchase Right”), each holder of 2020 Warrants will be entitled to acquire the aggregate amount of securities that the holder could have acquired if the holder had held the number of shares of common stock acquirable upon exercise of the applicable 2020 Warrant. However, to the extent that an exercise of a 2020 Purchase Right would exceed the Beneficial Ownership Limitation (defined below), then to such extent the 2020 Purchase Right will be held in abeyance until such time, if ever, that complete exercise of the 2020 Purchase Right would not exceed the Beneficial Ownership Limitation.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 9 -Common Stock Warrants and Common Stock Warrant Liability – (continued)

After the Initial Exercisability Date, the 2020 Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. If, at the time a holder exercises the 2020 Warrant (but not sooner than six months following the date of such warrant), a registration statement registering the issuance of the shares of common stock underlying the 2020 Warrants under the Securities Act is not then effective or available, nor is any current prospectus thereto available, and an exemption from registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the number of shares of common stock determined according to a formula set forth in the 2020 Warrant.

Limitations on Exercise. A holder (together with its affiliates) may not exercise any portion of the 2020 Warrants to the extent that the holder would own more than 4.99% of the outstanding common stock after exercise (the “Beneficial Ownership Limitation”), except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the 2020 Warrants. No fractional shares of common stock will be issued in connection with the exercise of a 2020 Warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

Except as otherwise provided in the 2020 Warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the 2020 Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, unless and until they exercise such warrants.

Common Stock Warrants Issued to Placement Agent in 2020 Registered Direct Offerings and Private Placement

In connection with the separate private placements concurrent with registered direct offerings of shares of the Company’s common stock in January and March 2020, the Company issued to H.C. Wainwright & Co., LLC, as placement agent, a warrant hasto purchase 13,228 shares of common stock and a warrant to purchase 13,313 shares of common stock. The warrants were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Terms used but not otherwise defined herein will have the meaning given them in the warrant, attached as Exhibit 4.2 to our Form 8-K filed on January 28, 2020 and our Form 8-K filed on March 6, 2020. These warrants have substantially similar featuresterms as the 2020 Warrants described above, except it is exercisable untilthat the earlierplacement agent warrant issued in January 2020 has an exercise price of (i) ten years$10.00 per share, and the placement agent warrant issued in March 2020 has an exercise price of $3.7563 per share.

Deemed Dividend Adjustment-Warrant Modified Terms Revaluation

On December 2, 2019, in connection with the settlement of a filed lawsuit against the Company on February 20, 2018 by New Enterprises, Ltd. (“New Enterprises”), the Company agreed to modify the terms of 6,934 common stock warrants that were originally issued to New Enterprises between September 2015 and February 2016. Specifically, the original strike price was reduced to $20.00 per warrant from $150.00 per warrant and the expiration date of grant; (ii)these warrants was extended one year to December 13, 2018,2020.

Per guidance of ASC 260, the second anniversaryCompany recorded a deemed dividend of $11 on the closing6,934 unexercised warrants that were affected by the modification of our initial public offering of common stock; and (iii)terms. The dividend was calculated as the closing of a liquidation, dissolution or winding up of the Company. The estimateddifference between the fair value of the common stock warrant onwarrants immediately prior to modification of terms and immediately after the date of grant was $537 as determined byadjustment using a Black-Scholes option pricingBlack Scholes model based on the following significant inputs: On December 2, 2019: common stock price of $7.575;$12.00; comparable company volatility of 60.9%73.2%; expectedremaining term of 6.250.01 years; risk-free rate of 2.09%; and dividend yield of 0%. The Company recorded the fair value and risk-free interest rate of the warrant as stock-based compensation expense within general1.63. As adjusted, common stock price of $12.00; comparable company volatility of 73.2%; remaining term 1.01 years; dividend yield of 0% and administrative expense in the accompanying statementsrisk-free interest rate of operations and comprehensive loss in 2015.1.63. 

 

Northern Arizona University Common Stock Warrant

In November 2015,On March 3, 2020, the Company issued an aggregate of 51,414 common shares in a common stock warrant to purchase 210,526 sharescashless exercise of common stock at56,625 warrants issued in December 2016 and November 2017. Consideration for the exercise of these warrants was the full settlement of an exercise priceoutstanding litigation reserve of $15.00$238,000.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share to Northern Arizona University (“NAU”) as part of the consideration given with the Series A convertible preferred stock in exchange for the full cancellation of a promissory note that had been previously issued to NAU.data)

 

Note 1210 - Stockholders’ Deficit

Capital Stock

The Company was organized under the laws of the state of Nevada on July 27, 2004 and was subsequently reincorporated under the laws of the state of Delaware on November 10, 2015. In connection with the reincorporation, as approved by the stockholders, the Company changed its authorized capital stock to consist of (i) 100 million shares of common stock, $.001 par value, and (ii) 2 million shares of preferred stock, $0.001 par value, designated as Series A convertible preferred stock. In December 2015, the Company amended its Certificate of Incorporation to change its authorized capital stock to provide for 15 million authorized shares of preferred stock of which 7,515,000 was designated as Series B convertible preferred stock, par value $.001 per share.

Prior to November 10, 2015, the Company’s authorized capital stock consisted of 100 million shares of common stock, $.001 par value, and 10 million shares of preferred stock, $.001 par value.

 

Common Stock

 

The Company had 10,363,1891,819,981 and 10,157,2921,414,671 shares of common stock issued and outstanding as of September 30, 2017March 31, 2020 and December 31, 2016,2019, respectively.

During the ninethree months ended September 30, 2017,March 31, 2020, the Company issued an aggregate of 205,897405,310 shares of common stock as follows: 48,240 shares to consultants for services, valued at $137, to settle previous claims; 14,014 shares for the cashless exercise of vested stock options; and 143,643 shares for net settlement of restricted stock units that vested during the period.

 


an aggregate of 177,500 shares in connection with a registered direct offering generating net proceeds to the Company in January 2020 of approximately $1.2 million, as further described below;

an aggregate of 176,372 shares in connection with a registered direct offering generating net proceeds to the Company in March 2020 of approximately $0.5 million, as further described below;

an aggregate of 51,414 shares for the exercise of outstanding warrants in settlement of an outstanding litigation reserve of $238,000 (see Note 9 — Common Stock Warrants and Common Stock Warrant Liability for further details); and

an aggregate of 24 shares for true up of shares as a result of the 1-for-20 reverse stock split effected in February 2020.  

Rights OfferingRegistered Direct Offerings

 

In April 2016,On March 6, 2020, the Company offeredclosed a registered direct offering of an aggregate of 176,372 shares of our common Stock at a purchase price of $3.005 per share for aggregate gross proceeds of approximately $0.5 million, before deducting fees payable to the existing holdersplacement agent and other estimated offering expenses payable by us. In addition, we also issued warrants exercisable for an aggregate of up to 176,372 shares of (i) itsour common stock and (ii) Series B convertible preferred stock,with an exercise price of $2.88 per share. In addition, in each case, as of April 8, 2016 (the “Record Date”), at no charge, non-transferable subscription rights, on a pro rata basis,connection with the offering, we issued the placement agent five-year warrants to purchase up to 13,228 shares of our common Stock at an exercise price of $3.7563 per share.

On January 28, 2020, the Company closed a registered direct offering of an aggregate of 177,500 shares of our common stock at a subscriptionpurchase price of $2.50$8.00 per share (the “Rights Offering”).for aggregate gross proceeds of approximately $1.42 million, before deducting fees payable to the placement agent and other estimated offering expenses payable by us. In addition, in a concurrent private placement, we also issued and sold warrants exercisable for an aggregate of up to 177,500 shares of our common stock with an exercise price of $9.00 per share. In connection with the holders also hadoffering, we issued the rightplacement agent five-year warrants to purchase additionalup to 13,312 shares of our common stock if any shares remain unsubscribed. The Company offered subscription rights on 5,794,162 sharesat an exercise price of its common stock. The Rights Offering was conducted as a private placement on a “best efforts” basis, with no minimum subscription required.$10.00 per share.

 

The subscription rights were initially exercisable beginning on April 8, 2016 and expiring on April 29, 2016 (the “Subscription Period”). However, the Company reserved the right to extend the Subscription Period for up to two additional weeks. The Company extended the Subscription Period for one additional week. The Rights Offering closed on May 6, 2016.22

 

The Company issued 2,478,486 shares of common stockSENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and received aggregate consideration of $6,199 in the Rights Offering. The aggregate consideration received consisted of: (i) $5,284 in cash; (ii) $821 in consideration paid through the cancellation of $821 in outstanding principal amount (and related unpaid interest) under certain outstanding unsecured notes; and (iii) the extinguishment of $94 in amounts owed by the Company for services and related miscellaneous expenses. Such cash proceeds will be used for working capital and general corporate purposes. As the Rights Offering was offered to certain existing holders of the Company’s stock, the shares sold are treated as outstanding from the date of their issuance in the computation of loss per share basic and diluted in future periods.data)

 

Note 1311 -Stock-based Compensation

 

Effective December 2008, the Company established the 2008 – 2009 Non-Qualified Stock Option Plan (the “2008 – 2009 Plan”) under which no stock options remain outstanding at September 30, 2017. The stock-based awards were issued with a price not less than $15.00 per share or 100% of the fair value of a share of common stock on the date of grant. After July 2015, no further awards were granted under the 2008 – 2009 Plan.

Effective July 2015,On June 12, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”) to replace the Company’s 2015 Equity Incentive Plan (the “2015 Plan”), which permits. The 2018 Plan authorized the issuance of 50,000 shares of our common stock. In addition, up to 2,000,000 shares reserved for the grant of stock options, stock appreciation rights, restricted stock units and other stock-based awards for employees, directors or consultants of the Company. The Board of Directors and the Company’s stockholders approved an additional 1,000,000143,714 shares of our common stock previously reserved for issuance under the 2015 Plan. The stock-basedPlan became available for issuance under the 2018 Plan to the extent such shares were available for issuance under the 2015 Plan as of June 12, 2018 or subsequently cease to be subject to awards outstanding under the 2015 Plan, such as by expiration, cancellation, or forfeiture of such awards.

Options are generally issued with a per share exercise price equal to no less than fair market value of our common stock at the date of grant. Options granted under the 20152018 Plan generally vest immediately, or ratably over a two- to 36-month period coinciding with their respective service periods; however, participants may exercise their options prior to vesting as provided by the 2015 Plan. Unvested shares issued for option exercised early may be subject to a repurchase by the Company if the participant terminates at the original exercise price.periods. Options under the 20152018 Plan generally have a contractual term of five or ten years. Certain stock option awards provide for accelerated vesting upon a change in control.

As of September 30, 2017,March 31, 2020, the Company had 779,09533,758 shares of common stock available for issuance under the 20152018 Plan.

 

The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, directors and consultants on the date of grant using the Black-Scholes option pricing model. The fair value of equity instruments issued to non-employees is re-measured as the award vests. The Black-Scholes valuation model requires the Company to make certain estimates and assumptions, including assumptions related to the expected price volatility of the Company’s stock, the period under which the options withwill be outstanding, the rate of return on risk-free investments, and the expected dividend yield for the Company’s stock.

  

The Company did not issue any option grants in the three months ended March 31, 2020.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1311 - Stock-based Compensation - (continued)

The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the nine months ended September 30, 2017, were as follows:

EmployeeNon-Employee
Expected volatility73.8% -83.7% N/A
Expected dividend yield N/A
Expected term (in years)3.0 to 3.5 N/A
Risk-free interest rate1.45%-1.94% N/A

 

Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined based on historical volatilities from traded options of biotech companies of comparable in size and stability, whose share prices are publicly available. The expected term of options granted to employees is calculated based on the mid-point between the vesting date and the end of the contractual term according to the simplified method as described in SEC Staff Accounting Bulletin 110 because the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its awards have been outstanding. For non-employee options, the expected term of options granted is the contractual term of the options. The risk-free interest rate is determined by reference to the implied yields of U.S. Treasury securities with a remaining term equal to the expected term assumed at the time of grant. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.

 

The following table summarizes the stock option activity, for both equity plans, for the periods indicated as follows:

 

  Number of
Options
  Weighted
Average
Exercise
Price Per
Share
  Weighted
Average
Remaining
Contractual
Term
(years)
  Aggregate
Intrinsic
Value(1)
  Number of
Options
  Weighted
Average
Exercise
Price Per
Share
  Weighted
Average
Remaining
Contractual
Term
(years)
  Aggregate
Intrinsic
Value (1)
 
Outstanding at December 31, 2016   1,477,300   1.61   5.8  $9,662 
Outstanding at December 31, 2019  136,489  $28.00   3.9  $   - 
Granted   161,500  $8.04   5.0  $   -  $-   -  $- 
Exercised   (15,000) $0.50         -  $-   -  $- 
Forfeited     $         (250) $-   -  $- 
Expired   (65,000) $10.22         -  $-   -  $- 
Outstanding at September 30, 2017   1,558,800   1.73   5.1  $183 
Exercisable at September 30, 2017   1,263,599  $1.08   4.8  $968 
Outstanding at March 31, 2020  136,239  $27.90   3.1  $- 
Exercisable at March 31, 2020  94,298  $30.52   2.8  $- 

 

(1)The aggregate intrinsic value onin the table was calculated based on the difference between the estimated fair market value of the Company’s stock and the exercise price of the underlying option.options. The estimated stock values used in the calculation was $1.85were $2.07 and $8.15$11.00 per share at September 30, 2017for the three months ended March 31, 2020 and the year ended December 31, 2016,2019, respectively.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the three months ended March 31, 2020:

  Number of
Units
  Weighted Average
Grant-Date Fair
Value Per
Unit
 
Outstanding as of December 31, 2019  5,877  $30.28 
Granted  -  $- 
Vested  -  $- 
Forfeited  -  $- 
Outstanding as of March 31, 2020  5,877  $30.28 

The stock-based compensation expense was recorded as follows:

  Three Months Ended
March 31,
 
  2020  2019 
Research and development $3  $9 
Selling, general and administrative  148   243 
Total stock-based compensation expense $151  $252 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1311 - Stock-based Compensation – (continued)

 

The stock-based compensation expense was recorded as follows:

  Three Months Ended September 30 Nine Months Ended September 30, 
  2017 2016 2017 2016 
Research and development $85  135 $269 $309 
General and administrative  861  798  2,549  2,097 
Total stock-based compensation expense $946  933 $2,818 $2,406 

The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee.

 

At September 30, 2017,March 31, 2020, the total compensation cost related to non-vestedunvested options and unvested restricted stock units not yet recognized was $1,942,$818, which will be recognized over a weighted average period of four years,24 months, assuming the employees and non-employees complete their service period required for vesting.

Effective December 2008, the Company established the 2008-2009 Plan under which no stock options remain outstanding at September 30, 2017. The stock-based awards were issued with a price not less than $15.00 per share or 100% of the fair value of a share of common stock on the date of grant. After July 2015, no further awards were granted under the 2008 – 2009 Plan.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2017:

   Number of
 Units
  Weighted
Average
Grant-Date Fair
Value Per Units
 
Outstanding as of December 31, 2016   455,430  $0.76 
Granted   117,885(1) $6.95 
Vested   (228,333) $2.00 
Forfeited     $ 
Outstanding as of September 30, 2017   344,982(2) $2.05 

(1)40,000 restricted stock units were granted on March 27, 2017 with a weighted average grant date fair value of $8.35, 17,885 restricted stock units were granted on May 19, 2017 with a weighted average grant date fair value of $6.99 and 60,000 restricted stock units were granted on June 19, 2017 with a weighted average grant date fair value of $6.00.

(2)At September 30, 2017, the total compensation cost related to non-vested restricted stock units not yet recognized was $1,075, which will be recognized over a weighted average period of 1.3 years, assuming the recipients complete their service period required for vesting.

24

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 14 - License and Other Agreements

Neogen Corporation

In May 2014, the Company entered into an exclusive license agreement with Neogen Corporation (“Neogen”). The Company granted an exclusive license to Neogen to (i) use the Company’s intellectual property (“IP”), consisting primarily of the ContraPest technology and (ii) manufacture, distribute and sell commercial rodent control products in the United States and certain U.S. territories, Canada and Mexico.

As previously disclosed in our Current Report on Form 8-K dated and filed January 23, 2017, on January 23, 2017 we entered into a termination agreement (the “Settlement Agreement”) with Neogen Corporation (“Neogen”). Pursuant to the Settlement Agreement, the parties agreed to (a) terminate the existing Exclusive License Agreement between us and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or us having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”), as further described below; and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. As part of the Settlement Agreement, we agreed to pay to Neogen upon the execution of the Settlement Agreement an aggregate of $1,000 in settlement of all claims.

For the nine months ended September 30, 2017 and the year ended December 31, 2016, the Company recognized revenue of $0 and $186, respectively, under the License Agreement.

Bioceres/INMET S.A. Agreement

In January 2016, the Company entered into a services agreement with Bioceres, Inc. (“Bioceres”), a wholly-owned subsidiary of Bioceres S.A., a leading agricultural biotechnology company in Argentina, and its Argentinean subsidiary, Ingenieria Metabolica S.A. (“INMET”) to develop a production method for synthetic triptolide, the main ingredient in ContraPest. The Company also entered into an agency agreement with INMET whereby the Company appointed INMET as its exclusive agent to seek regulatory approval for and conduct pre-sales and marketing of its product, ContraPest, in Argentina. The Company and INMET have also agreed to manufacture and distribute its product in Argentina and other countries, as mutually agreed, through a newly formed entity.

The term of the service agreement is for two years. The service agreement can be terminated at any time upon written notice by either party for any reason. The term of the agency agreement with INMET is the earlier of: (i) when the Company and INMET incorporate the joint venture entity in Argentina or (ii) January 2018.

At September 30, 2017, the Company had accrued expenses of $100 due to Bioceres as detailed in the table or accrued expenses in Note 7


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1512 - Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

 

Neogen Settlement AgreementOn April 20, 2018, the Company’s former Executive Vice President and Chief Operating Officer Andrew Altman filed a charge of employment discrimination with the Equal Employment Opportunity Commission (EEOC) against the Company. Mr. Altman claimed that he was terminated after he expressed opposition to an email Cheryl Dyer, former Chief Research Officer, had sent out to the management team, in which she criticized a Mormon newspaper. The Company filed a position statement on May 21, 2018. No substantive action has been taken since then, and the Company has not heard anything further either from Mr. Altman’s attorneys. On February 28, 2020, the EEOC issued a Dismissal and Notice of Rights to the Company closing its file on the charge on the basis that the EEOC was unable to conclude that the information obtained established violations of the relevant statutes.

  

See Note 14 above with regardsLease Commitments

The Company is obligated under finance leases for certain research and computer equipment that expire on various dates through April 2022. At March 31, 2020, the gross amount of office and computer equipment, and research equipment and the related accumulated amortization recorded under the finance leases was $478 and $291, respectively.

In February 2012, the Company entered into an operating lease for its then corporate headquarters in Flagstaff, Arizona. The lease was originally due to expire in January 2015. In December 2013, the Company amended its lease to expand into the remaining area in the building and extended the term to December 31, 2019. In February 2014, the Company further amended the lease to expand into an adjacent building. The lease requires escalating rental payments over the lease term. Minimum rental payments under the operating lease are recognized on a straight-line basis over the term of the lease and accordingly, the Company records the difference between the cash rent payments and the recognition of rent expense as a deferred rent liability. The lease is guaranteed by the former President of the Company. In December 2019, we extended the current lease for only our manufacturing facilities located in Flagstaff, Arizona, occupying a total of 7,632 square feet of space. The lease for our manufacturing facilities expires in December 2020.

On November 16, 2016, we leased an additional 1,954 square feet of research and development space, also in Flagstaff. This lease expired on November 15, 2018 but was extended for an additional 24 months, through November 2020. A subsequent amendment to the Settlement Agreement with Neogen.

Although notice of the legal action by Neogen and the Settlement Agreement with Neogen, occurred after December 31, 2016, as per the provisions of Accounting Standards Codification Topic 450 Loss Contingencies, included in the financial statements oflease allows for the Company to cancel the lease at December 31, 2016 isany time through the lease term with 30 days’ notice. The Company provided a $1,000 charge to general and administrative expenses and a corresponding accrual of contract30-day cancellation settlement agreement related to this agreement.notice effective February 2020.

 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1512 - Commitments and Contingencies(continued)

 

ResolutionOn December 1, 2019, we entered into a lease for our corporate headquarters in Phoenix, Arizona where we lease and occupy approximately 5,529 square feet of Disputeoffice space. This lease expires in November 2024.

 

In recognition of his continued supportWe believe that our existing facilities are adequate and cooperation,meet our current needs for business, manufacturing and to resolve a dispute regarding whether his options appropriately expired in the first quarter of 2016, in July 2016, the Company’s Board of Directors agreed to issue to its former chief executive officer 120,000 shares of the Company’s common stock. The expense of $300 associated with this full and final settlement was recorded at December 31, 2016.

Lease Commitmentsresearch.

 

Rent expense was $246$69 and $234$68 for the ninethree months ended March 31, 2020 and year ended September 30, 2017 and December 31, 2016,2019, respectively. The future minimum lease payments under non-cancellable operating lease and future minimum capitalfinance lease payments as of September 30, 2017March 31, 2020 are follows:

 

  Capital
Leases
  Operating
 Lease
 
Years Ending December 31,        
2017 $25  $63 
2018  96   258 
2019  88   221 
2020  67    
2021  84    
Total minimum lease payments $360  $542 

  Finance
Leases
  Operating
Lease
 
Years Ending December 31,      
2020  50   174 
2021  58   136 
2022  28   138 
2023  -   141 
2024  -   132 
Total minimum lease payments $136  $721 

 

 Capital
Leases
  Finance
Leases
 
Less: amounts representing interest (ranging from 7.25% to 11.56%) $75 
   
Less: amounts representing interest (ranging from 7.2% to 18.3%) $16 
       
Present value of minimum lease payments 285   120 
       
Less: current installments under capital lease obligations  70 
Less: current installments under finance lease obligations  55 
       
Total long-term portion $215  $65 

SENESTECH, INC. 

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1613 - Subsequent Events

 

The travel and other restrictions that started in March in response to the COVID-19 pandemic resulted in a significant slowdown in our field studies and sales efforts.  We were able to resume some projects by late-April, however, we still have delays on certain projects that might remain on hold until the lifting of government restrictions.  These delays could impact our results in future quarters. In Octoberaddition, stay at home orders have severely limited our ability to communicate with current and potential commercial customers. COVID-19 is also placing a significant burden on federal, state and local governments which may impede or delay our ability to sell our products to them.

On April 15, 2020, we entered into a loan agreement with BMO Harris Bank National Association as the lender in an aggregate principal amount of 2017,$645,700 pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The loan is evidenced by a promissory note dated April 15, 2020 and matures April 15, 2022. The loan bears interest at a rate of 1.00% per annum and contains customary events of default including, among other things, payment defaults. The loan closed and was funded April 20, 2020. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. The loan is subject to forgiveness to the extent proceeds are used for qualifying expenses, including certain payroll, utility, rent and mortgage interest expenses. No assurance is provided that the Company will obtain forgiveness of the loan in whole or in part.

On April 24, 2020, the Company closed a public offering of 145,586 Class A Units and 1,428,722 Class B Units. Each unit is comprised of one share of common stock, par value $0.001 per share or common stock equivalent in the form of a pre-funded warrant and one warrant to purchase one share of common stock. The Class A Units were offered at a public offering price of $3.176 per unit, and the Class B Units were offered at a public offering price of $3.175 per unit priced at-the-market under Nasdaq rules.

The Company estimates that the net proceeds from the Public Offering will be approximately $4.3 million assuming the full exercise of the pre-funded warrants sold in this offering after deducting certain fees due to the placement agent and other estimated transaction expenses. The net proceeds received by the Company from the transactions will be used to fund working capital and other general corporate purposes, including the Company’s commercialization efforts of ContraPest.

In April and May 2020, the Company issued 26,308an aggregate of 1,428,722 shares for the exercise of the pre-funded warrants noted above. The net proceeds to the Company for these exercises were $14.

In April 2020, the Company issued 666 shares of its common stock to two executives ofin the Company in net settlement of restricted stock units that vested on September 30, 2017 but were not issued until October 2, 2017.

during the period.


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

As used in this Quarterly Report on Form 10-Q, “SenesTech,” the “Company,” “we,” “us,” or “our” and “the Company” refer to SenesTech, Inc., a Delaware corporation.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with   our condensed consolidated financial statements and related notes.

Forward-Looking Statements

Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, notes to our condensed consolidated financial statements and elsewhere in this Quarterly Report on Form 10-Qreport are not historical facts but are forward-lookingforward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can   identify forward-lookingforward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,”   “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to, statements about our plans, objectives, expectations and intentions and other statements that are not historical facts. Specific examples of forward-looking statements include those concerning the sufficiency of our cash and future revenue to fund operations, our expectations as to expenses, future revenue and the commercialization of our products, our research and development plans and initiatives and the development of our products. to:

The impacts and implications of the COIVD-19 pandemic;

Our commercialization and promotion strategy and plans, including key elements to our business strategy, how we commercialize, our sales approach, our areas and markets of focus, our pricing strategy, our strategic relationships and which geographic markets we target;

The potential market opportunities for commercializing our product candidates and the role we expect ContraPest to hold within the market;

Our seeking, obtaining or maintaining regulatory approvals for our product candidates;

The anticipated results and effects of our products, including those indicated in studies;

Our expectations regarding the potential market size for our products and how the market may develop;

Our estimates or expectations related to our revenue, cash flow, expenses, capital requirements and need for additional financing;
Our ability to improve our cost structure and gross margins, and limit our cash burn;
Our plans for our business, including for research and development;

Our ability to enter into strategic arrangements and to achieve the expected results from such arrangements;

The initiation, timing, progress and results of field studies and other studies and trials and our research and development programs;

Our ability to develop and manufacture our products candidates to meet demand and in a commercially efficient manner;

The scope of protection we are able to obtain and maintain for our intellectual property rights covering our product candidates;

Our financial performance, including our ability to fund operations;

Developments and projections relating to our projects, competitors and our industry;

Our expectation regarding our ability to sell our products at commercially reasonable values;

Our beliefs and expectations related to pending litigation; and

Other risks and uncertainties, including those described or incorporated by reference under the caption “Risk Factors” in our 2019 Annual Report.


These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or   our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part III of our Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 20162019, filed with the SEC on March 17, 2020 and April 21, 2020, respectively, (collectively, the “2019 Annual Report”), and Item 1A of Part II of this Form 10-Q, in each case entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

All amounts shown in the following Management’s Discussion and Analysis of Financial Condition and Results of Operations are full amounts (and are not shown in thousands).

 

Overview

 

Since our inception, in 2004, we have devoted substantially allsustained significant operating losses in the course of our resources to organizing and staffing our company, conducting research and development activities and expect such losses to continue for our product candidates, business planning, raising capital and acquiring and developing product and technology rights. Until August 2016, we did notthe near future. We have any products approved for sale, and we have not generated any significantlimited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to date.prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date with proceeds fromthrough the sale of equity securities, including convertible preferred stock, common stock and preferred stock, the issuancewarrants to purchase common stock.

We have also raised capital through debt financing, consisting primarily of convertible and other promissory notesnotes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through September 30, 2017,March 31, 2020, we had received net proceeds of $49.2$68.9 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $1.6$0.6 million from research grantsin net product sales. At March 31, 2020, we had an accumulated deficit of $98.6 million and licensing fees.cash and cash equivalents of $1.5 million.

 

We have incurred significant operating losses every year since our inception. Our net losses were $2.9 million, $10.0 million and $11.0$2.7 million for the three and nine months ended September 30, 2017March 31, 2020 and $2.4 million for the yearthree months ended DecemberMarch 31, 2016, respectively. As of September 30, 2017, we had an accumulated deficit of $71.3 million.2019. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.

 

We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.

 

As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for each of the ninethree months ended September 30, 2017March 31, 2020 and September 30, 2016March 31, 2019 was $2.8 million$151,000 and $2.4 million,$252,000, respectively, which represented 28.1%6.4% and 33.0%10.6%, respectively, of our total operating expenses for those periods.


We will need additional funding in order to continue to fund our operations and achieve profitability and become cash flow positive and will continue to seek additional financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations.

While the effects of the COVID-19 pandemic did not have a significant impact on revenue during our first quarter, the travel and other restrictions that started in March resulted in a significant slowdown in our proof of concept field studies and sales efforts. We were able to resume field studies in some important projects by late-April and initially believed that we would re-start all our most significant field studies as we obtained limited waivers of certain travel bans; however, we still have delays on certain projects that might remain on hold until the lifting of government restrictions. These delays could impact our results in future quarters. Initially, we believed that pest control would continue through the pandemic as a necessity and we were and have been able to maintain our manufacturing with cautionary, best practices put in place. However, we have concerns over distributor, pest control operator and individual consumer spending as restrictive measures related to the pandemic continue. Stay at home orders across the world have impeded our ability to communicate with current and prospective customers, potentially reducing sales until the orders are lifted. In addition, federal, state and municipal budgets are under severe strain as a result of the pandemic. This may delay or impede their ability to make near term purchases of our products. While we have stocked certain long lead time inventory raw material ingredients, any prolonged impact on the suppliers we rely on for the purchase of these items by the COVID-19 pandemic could impact future manufacturing operations. 

 

Components of our Results of Operations

 

RevenueNet Sales

 

To date, we have generated $34,000, from productNet sales are comprised primarily of sales, net of discounts and we expectpromotions, of ContraPest and related components, to generate increased revenue from the sale of products or royalties in the fourth quarter of 2017. Except for the minimal product sales noted above, all our revenue to date has been derived from payments received in connection with research grantsdistributors and licensing fees received as a result of our execution of the former license agreement with Neogen.


We recognized product sales revenue of $17,000 and $-0- for the three months ended September 30, 2017 and 2016, respectively, and $34,000 and $-0- and for the nine months ended September 30, 2017 and 2016, respectively. In addition, for the nine months ended September 30, 2016, we recognized revenue of $139,000 under our former license agreement with Neogen and $122,000 under NIH grants. We do not anticipate additional grant revenue under the NIH grants or additional revenue from our former license agreement with Neogen.customers. 

 

Operating Expenses

 

Research and Development Expenses

 

Research and development expenses consist primarily of costs incurred in connection with the discoveryresearch and development of ContraPest and our other product candidates, which include:

 

 Employee-relatedEmployee related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;

 

 Expenses incurred in connection with the development of our product candidates; and

 

 Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.


We expense research and development costs as incurred.

 

At this time, we cannot reasonably estimate the costs for completing the development of ContraPest or the cost associated with the development of any of our other product candidates.

We plan to continue to hire employees to support our research and development efforts and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain employees for our research and development efforts. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our research and development expenses for the foreseeable future.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.

We anticipate that our general and administrative expenses may increase in the future as we increase our headcount to support commercialization of any approved products and further development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

We plan to continue to hire employees to support our commercialization of any approved products and further development of our product candidates, and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our general and administrative expenses for the foreseeable future.

Other Income (Expense), Net

Interest Income. Interest income consists primarily of interest income earned on cash and cash equivalents. Our interest income has not been significant due to nominal cash and investment balances and low interest earned on invested balances.


Interest Expense. Interest expense in 2017 consists primarily of interest accrued on our lease and note commitments. Interest expense in 2016 consisted primarily of interest on $2.9 million in convertible and other promissory notes we issued during 2014, 2015 and 2016, most of which was converted or redeemed by December 31, 2016.

Other Income (Expense), Net. Other income (expense), net; consists primarily of net losses on extinguishment of convertible and non-convertible, secured and unsecured promissory notes.

Income Taxes

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December 31, 2016, we had federal net operating loss carryforwards of $34.0 million which begin to expire in 2021 and state net operating loss carryforwards of $27.8 million which began to expire in 2016, unless utilized.


Comparison of the Three and Nine Months Ended September 30, 2017 and 2016

The following table summarizes our results of operations for the three and nine months ended September 30, 2017 and 2016:

SENESTECH, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except shares and per share data)

(Unaudited)

  For the Three Months  For the Nine Months 
  Ended September 30,  Ended September 30, 
  2017  2016  2017  2016 
Revenue:            
License revenue $  $131  $  $261 
Product Sales  17      34    
Total revenue  17   131   34   261 
Cost of goods sold  11      27    
Gross profit  6   131   7   261 
                 
Operating expenses:                
Research and development  721   829   2,517   1,964 
General and administrative  2,235   1,932   7,506   5,259 
Total operating expenses  2,956   2,761   10,023   7,223 
                 
Net operating loss  (2,950)  (2,630)  (10,016)  (6,962)
                 
Other income (expense):                
Interest income  9      20    
Interest expense  (33)  (6)  (54)  (49)
Interest expense, related parties     (9)  (1)  (43)
Loss on extinguishment of unsecured promissory note     (59)     (171)
Other income (expense)  37      76   51 
Total other income (expense)  13   (74)  41   (212)
                 
Net loss  (2,937)  (2,704)  (9,975)  (7,174)
                 
Series A convertible preferred stock dividends     (30)     (90)
                 
Net loss and comprehensive loss $(2,937) $(2,734) $(9,975) $(7,264)

Three Months Ended September 30, 2017 compared to Three Months Ended September 30, 2016:

Revenue

Revenue was $17,000 for the three months ended September 30, 2017, compared to $131,000 for three months ended September 30, 2016.

The $17,000 revenue recognized for the three months ended September 30, 2017 represented sales of our product, ContraPest. The $131,000 of revenue for the three months ended September 30, 2016, was earned from research grants and from our former license agreement with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 under this agreement.

Cost of Goods Sold

Cost of goods sold was $11,000 for the three months ended September 30, 2017, compared to $-0- for three months ended September 30, 2016. The increase in cost of goods sold corresponded to the product launch of ContraPest.


Research and Development Expenses

  Three Months Ended
September 30,
  Increase / 
  2017  2016   (Decrease) 
  (in thousands) 
Direct research and development expenses:            
Unallocated expenses:            
Personnel related (including stock-based compensation) $449  $701  $(252) 
Professional Fees/Consultants  39   10   29 
Facility related  76   51   25 
Other  157   67   90 
Total research and development expenses $721  $829  $(108) 

Research and development expenses were $721,000 for the three months ended September 30, 2017, compared to $829,000 for the same period in 2016. The $108,000 decrease in research and development expenses was primarily due to a decrease of $252,000 in personnel-related costs, offset by increases in professional fees/consultant expenses of $29,000, facility expenses of $25,000 and other expenses of $90,000. The decrease in personnel-related costs resulted from lower research and development salaries of $219,000 due to reduced headcount and a decrease in stock-based compensation expense of $50,000, offset by higher payroll taxes of $17,000. Professional services and consulting expenses increased $29,000 for the three months ended September 30, 2017, compared to the same period in 2016 primarily due to an increase in synthetic triptolide research fees and legal fees. Rent and utilities for the three months ended September 30, 2017 increased $25,000 over the same period in 2016 due primarily to the expansion into the research space at Northern Arizona Center for Entrepreneurship and Technology (“NACET”) facility. Other expenses increased by $90,000 from $67,000 for the three months ended September 30, 2017 as compared to the same period in 2016, primarily due to increased travel expenses of $34,000 related to field team support due to on-site evaluations of potential customers and research operations and increased depreciation expense of $70,000 due to fixed asset additions in our research operations offset by lower lab fees of $14,000. As noted last quarter, we have now filed in all 50 states and the District of Columbia and have begun the process of refiling in some states.

We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates. At this time, we cannot reasonably estimate the costs for further development of ContraPest or the cost associated with the development of any of our other product candidates.

 

Selling, General and Administrative Expenses

 

General and administrative expenses were $2.2 million for the three months ended September 30, 2017, compared to $1.9 million for the three months ended September 30, 2016. The increase of $0.3 million inSelling, general and administrative expenses was dueconsist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, sales, marketing and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.

We continue to an increasefocus on improving our cost structure, with the goals of $228,000shifting resources to commercialization, significantly reducing our year over year burn rate and achieving a 50% or greater gross margin. Steps have included relocating to more cost-efficient space, organizational restructuring, and improving our manufacturing and supply processes and reducing staffing. We expect to see the benefit to costs of these steps in personnel relatedthe coming quarters.

We plan to continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our selling, general and administrative expenses an increasefor the foreseeable future.

Interest Income

Interest income consists primarily of $89,000 in insurance expenses related to the increased D&O insurance expense as a public company, an increase of $18,000 in non-capitalized furnitureinterest income earned on cash and computer equipment and an increase in occupancy expenses of $8,000, offset by a $24,000 decrease in professional services fees due primarily to lower audit and accounting fees and a $20,000 reduction in travel and entertainment expenses. The increase in personnel related expenses consisted of an increase of $144,000 in net additional salary costs, an increase in stock based compensation of $61,000, an increase in payroll taxes and processing fees of $35,000 and an increase of $32,000 in recruiting expenses offset by a $44,000 reduction in employee benefits due to reduced relocation and benefits costs.cash equivalents.

 

Interest Expense

 

We recorded $24,000Interest expense consists primarily of interest expense, net for the three months ended September 30, 2017, compared to $6,000 for the same period in 2016. The increase in interest expense of $18,000 was the result of increased debt in the form of notes payableaccrued on our finance lease and leases on equipment acquisitions during 2017.note commitments.

 

Other Income (Expense), Net

 

We recorded $37,000Other income (expense), net, consists primarily of otherrecognized change in value of short-term investments and income net for the three months ended September 30, 2017, compared to $59,000 of other expense for the same period in 2016. The $96,000 net decrease in other expense was primarily due to lower expense(expense) related to the year-over-year fair market value adjustment of our convertible promissory notesderivative warrant.

Income Taxes

Deferred tax assets and lossesliabilities are determined based on differences between the financial statement and tax bases of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate has been affected by the full valuation allowance recorded since inception on the extinguishmentCompany’s deferred tax assets.

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net operating losses we have incurred in each year in our history or for our generated research and development tax credits, due to the uncertainty regarding our ability to realize a benefit from these tax attributes. At March 31, 2020, the Company has federal and state net operating loss carryforwards of said promissory notes.approximately $61.3 million and $47.8 million, respectively, not considering any potential IRC Section 382 annual limitation discussed below. The federal loss carryforwards begin to expire in 2023, unless previously utilized. Included in the $61.3 million of federal loss carryforwards are approximately $16.8 million of net operating losses that do not expire due to the tax law changes promulgated in conjunction with the Tax Cuts and Jobs Act of 2017.

 

Additionally, the utilization of the net operating loss and tax credit carryforwards could be subject to annual limitations under sections 382 and 383 of the Internal Revenue Code of 1986, and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by section 382, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under section 382. To the extent that a study is completed and an ownership change is deemed to have occurred, the Company’s net operating losses could be limited.


NineComparison of the Three Months Ended September 30, 2017 compared to Nine Months Ended September 30, 2016March 31, 2020 and 2019:

Revenue

Revenue was $34,000 for the nine months ended September 30, 2017, compared to $261,000 for nine months ended September 30, 2016.

 

The $34,000 revenue recognizedfollowing table summarizes our results of operations for the ninethree months ended September 30, 2017 representedMarch 31, 2020 and 2019:

  For the Three Months 
  Ended March 31, 
  2020  2019 
       
Revenue:      
Sales $37  $19 
Cost of sales  22   12 
Gross profit  15   7 
         
         
Operating expenses:        
Research and development  296   464 
Selling, general and administrative  2,045   1,904 
Total operating expenses  2,341   2,368 
         
Net operating loss  (2,326)  (2,361)
         
Other income (expense):        
Interest income  2   15 
Interest expense  (8)  (13)
Other income  15   (5)
Total other income (expense)  9   (3)
         
Net loss and comprehensive loss  (2,317)  (2,364)
Deemed dividend-warrant price protection-revaluation adjustment  414   - 
Net loss attributable to common shareholders $(2,731) $(2,364)
       
Weighted average common shares outstanding - basic and fully diluted  1,611,304   1,175,920 
         
Net loss per common share - basic and fully diluted $(1.69) $(2.01)

Net Sales

Net sales of our product, ContraPest. The $261,000 of revenuewere $37,000 for the ninethree months ended September 30, 2016 was earned from research grantsMarch 31, 2020, compared to $19,000 for the three months ended March 31, 2019. Sales increased $18,000 due to our shift to pull through sales strategy directed at consumers and from our former license agreement with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 underend users. This strategy has shown initial promise. However, the benefit of this agreement.strategy has been offset by reduced sales, reflecting reduced spending by customers due to COVID-19.

 

Cost of Goods SoldSales

 

Cost of goods soldsales was $27,000$22,000 or 59.5% of net sales for the ninethree months ended September 30, 2017,March 31, 2020, compared to $-0-$12,000 or 63.2% for ninethe three months ended September 30, 2016.March 31, 2019. The increase in cost of goods sold correspondedof $10,000 in 2020 is primarily due to the product launchhigher sales volume. The decrease in cost of ContraPest. Costsales as a % of net sales was due to reduced scrap expense and continued process improvement and efficiencies. We anticipate cost of goods sold as a percentage of sales will improve for the period was approximately 80%foreseeable future due to manufacturing inefficiencies surrounding the start-upefficiencies as a result of the new manufacturing line and the cost of replacement product shipped to replace damaged product.scale up activities.

 

Gross Profit

Gross profit for the three months ended March 31, 2020 was $15,000 or 40.5% of net sales, compared to a gross profit of $7,000 or 39.0% of net sales, for the same period in 2019. The increase in gross profit was a direct result of decreased scrap related to scale-up activities as well as continued process improvement and efficiencies.


Research and Development Expenses

 

 Nine Months Ended
September 30,
 Increase/  Three Months Ended
March 31,
 Increase 
(Decrease)
 
 2017  2016  (Decrease)  2020 2019    
 (in thousands)  (in thousands) 
Direct research and development expenses:                   
Unallocated expenses:                   
Personnel related (including stock-based compensation) $1,471  $1,384  $87  $137  $226  $(89)
Professional Fees/Consultants  272   142   130 
Facility related  228   157   71 
Facility-related  42   63   (21)
Other  546   281   265   117   175   (58)
Total research and development expenses $2,517  $1,964  $553  $296  $464  $(168)

 

Research and development expenses were $2.5 million$296,000 for the ninethree months ended September 30, 2017,March 31, 2020, compared to $2.0 million$464,000 for the same period in 2016.2019. The $500,000 increase$168,000 decrease in research and development expenses was partiallyprimarily due to an increasea decrease of $87,000 in personnel-related costs. This increase$89,000 in personnel-related costs, resulted from increasedincluding stock-based compensation expense, due to the classification of certain field support employees to sales and marketing. With more focus on the commercialization of ContraPest, it was determined that these certain field support employees previously classified as research and development salaries of $47,000are now refocused on sales and marketing efforts.

Facility-related expense decreased $21,000 due to headcount additions in 2017 and an increase in stock-based compensation expense of $40,000. Professional services and consulting expenses increased $130,000 for the nine months ended September 30, 2017 comparedprimarily to the same periodcancellation of a facility lease of 1,954 square feet of research and development space in 2016Flagstaff, Arizona.

The decrease in other research and development expenses of $58,000 was primarily due to an increase in synthetic triptolide research fees and legal fees.

State registration and filing fees increased $27,000 for the nine months ended September 30, 2017 compared to the same period in 2016 due to the increase in state filings and registrations as we have now filed in all 50 states and the Districta reclassification of Columbia and have begun the process of refiling in some states. Travelother expenses related to certain field team support increased $97,000 for nine months ended September 30, 2017 over the same period in 2016 dueemployees to on-site evaluations of potential customerssales and research operations. Rent and utilities for the nine months ended September 30, 2017 increased $51,000 over the same period in 2016 due to the expansion into the research space at our NACET facility. Depreciation expense increased $62,000 for the nine months ended September 30, 2017 over the same period in 2016 due to fixed asset additions in our research operations.marketing as described above.

 


We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredientingredients for our product candidates.

 

Selling, General and Administrative Expenses

 

GeneralSelling, general and administrative expenses were $7.5approximately $2.0 million for the ninethree months ended September 30, 2017,March 31, 2020, as compared to $5.3approximately $1.9 million for the ninethree months ended September 30, 2016.March 31, 2019. The increase of $2.2 million$100,000 in selling, general and administrative expenses was primarily due to an increasea decrease of $1.5 million$100,000 in personnel related expenses, an increasenet salary costs, a decrease of $30,000 in travel expenses, of $113,000, anoffset by a $165,000 increase in insurance expenseprofessional service fees and $65,000 in expenses related to restricted use field projects. The decrease in net salary costs of $248,000,$100,000 was due primarily to a $178,000 increase in office supplies and non-capitalized furniture and computer equipment and an increase in marketing,decrease of stock service and shareholder relations expenses of $23,000.compensation expenses. The increase in personnel relatedprofessional services expenses consisted of an increase in stock based compensation of $450,000 and an increase of $1.1 million in net additional salary costs. The increase in insurance was primarily due to increased directorlegal expenses related to litigation settlement and officer insurance as a result of the public becoming a public reporting company in December of 2016. Likewise, marketing,1-for-20 reverse stock servicesplit and shareholder relations expenses increased due to the Company becoming a commercial, public reporting company in December of 2016.common stock offerings. 

 

Interest Income/Expense, Net

 

We recorded $35,000interest expense of interest expense,$6,000, net, for the ninethree months ended September 30, 2017,March 31, 2020, as compared to $92,000interest income, net, of $2,000 for the same period in 2016.2019. The $8,000 decrease in interest expense of $57,000income was thea result of decreased interest income earned as a decreaseresult of $2.9 million in convertible notes that were issued in 2014lower average daily cash balance and exchanged for Series B convertible preferred stock in December 2016 partially offset by the increase in interest related to increased debt in the form of notes payable and leases on equipment acquisitions during 2017.year over year.

 

Other Income (Expense), Net

 

We recorded $76,000$15,000 of other income, net, for the ninethree months ended September 30, 2017,March 31, 2020, compared to $120,000$5,000 of other expense, net, for the same period in 2016.2019. The $196,000$20,000 net increase is due primarily to recognized gains of $15,000 during the three months ended March 31, 2020 and a decrease in other expense was primarily due to the expenseexpenses related to the year-over-year fair market value adjustment of our convertible promissory notes and losses on the extinguishment of said promissory notes.derivative warrant.


 

Liquidity and Capital Resources

 

Since our inception, we have sustained significant operating losses in the course of our research and development activities we have sustained significant operating losses and expectscommercialization efforts and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. During the first nine months of 2017, we began full scale marketing of our first product, ContraPest and we continue to develop other product candidates, which are in various phases of development. We have funded our operations to date primarily with proceeds fromthrough the sale of equity securities, including convertible preferred stock, common stock and preferred stock, the issuancewarrants to purchase common stock; debt financing, consisting primarily of convertible and other promissory notesnotes; and, to a lesser extent, payments received underin connection with product sales, research grants and pursuant to our former license agreement with Neogen. licensing fees. 

Through September 30, 2017,March 31, 2020, we had received net proceeds of $49.2$68.9 million from our sales of common stock, and preferred stock and warrant exercises and issuance of convertible and other promissory notes, and an aggregate of $1.6$1.7 million from licensing fees. fees and an aggregate of $0.6 million from product sales. At March 31, 2020, we had an accumulated deficit of $98.6 million and cash and cash equivalents of $1.5 million.

 

The Company’sOur ultimate success depends upon the outcome of a combination of factors, including: (i) the success of its research and development; (ii) ongoing regulatory approval andsuccessful commercialization of ContraPest and its othermaintaining and obtaining regulatory approval of our products and product candidates; (iii)(ii) market acceptance, and commercial viability and profitability of ContraPest and other products if the Company obtains the necessary regulatory approvals; (iv)products; (iii) the ability to market itsour products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow itsour business; and (vi) the timely and successful completion of additional financing as needed. The Company has funded its operationsour ability to date through the sale of convertible preferred stock and common stock, including an initial public offering of 1,875,000 shares of its common stock on December 8, 2016, debt financing, consisting primarily of convertible notes and, to a lesser extent, payments received in connection with research grants and licensing fees. As of September 30, 2017, we had an accumulated deficit of $71.3 million and cash and cash equivalents and highly liquid investments of $3,648.meet our working capital needs.

Based upon its current operating plan, the Company expects that cash and cash equivalents and highly liquid, short term investments at September 30, 2017, in combination with anticipated revenue,

We will be sufficient to fund its current operations for the near future. However, the Company is likely to requireneed additional capitalfunding in order to continue to fund its operating lossesour operations and researchachieve profitability and development activities by issuingbecome cash flow positive and will continue to seek additional debt and equity instruments, until such time as the Company is profitable.financing. If such equity or debt financing is not available at adequate levels the Company willor on acceptable terms, we may need to reevaluate its plans.

Off-Balance Sheet Arrangements

As of September 30, 2017, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

delay, limit or terminate commercialization and development efforts or discontinue operations.


 

Additional Funding Requirements

We expect our expenses to continue or increase substantially in connection with our ongoing activities, particularly as we advancefocus on marketing and sales of ContraPest. Further, the COVID-19 pandemic will likely delay completion of field studies and achievement of sales, which will further increase our product candidates in development.need for financing. In addition, we will continue to incur additional costs associated with operating as a public company.

In particular, we expect to incur substantial and increased expenses as we:

 

 Continue the research and development of ContraPest andChange our other product candidates, including engaging in any necessary field studies;work processes to address COVID-19 workplace changes;

 

 Seek ongoing regulatory approvals

Work to maximize market acceptance for, ContraPest and generate sales of, our other product candidates;

products;

 

 Scale up manufacturing processes and quantities to prepare for

Manage the commercialization of ContraPest and any other product candidates for which we receive regulatory approval;

Establish an infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;

 

 Attempt to achieve market acceptance for

Continue the development of ContraPest and our products;other product candidates, including engaging in any necessary field studies;

 

 ExpandSeek additional regulatory approvals for ContraPest and our other product candidates;

Scale up manufacturing processes and quantities to meet future demand of ContraPest and any other product candidates for which we receive regulatory approval;

Continue product development of ContraPest and advance our research and development activities and advance the discoveryresearch and development programs for other product candidates;

 

 Maintain, expand and protect our intellectual property portfolio; and

 

 

Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.

 

We believe we will need additional financing to fund these continuing and additional expenses.

Cash Flows

 

The following table summarizes our sources and uses of cash for each of the periods presented:

 

 Three Months Ended
March 31,
 
 Nine Months Ended
September 30,
  2020  2019 
 2017  2016    
Cash used in operating activities $(7,596) $(4,240) $(1,871) $(1,948)
Cash used in investing activities  (3,825)  (54)
Cash provided by financing activities  294   5,498 
Cash provided by (used in) investing activities  40   (11)
Cash provided by (used in) financing activities  1,387   (15)
Net increase (decrease) in cash and cash equivalents $(11,127) $1,204  $(444) $(1,974)

 

Operating Activities.

 

During the ninethree months ended September 30, 2017,March 31, 2020, operating activities used $7.6$1.9 million of cash, primarily resulting from our net loss of $10.0$2.3 million andoffset by changes in our operating assets and liabilities of $0.6 million, partially offset$233,000 and by non-cash charges of $3.0 million.$213,000, consisting primarily of stock-based compensation, depreciation and gains recognized on sale of equipment. Our net loss was primarily attributedattributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the ninethree months ended September 30, 2017March 31, 2020 consisted primarily of a decreasenet increase in prepaid expenses of $165,000 and a decrease in receivables of $3,000 and an increase in deferred rent of $12,000,$40,000 offset by a net decrease in accrued expenses and accounts payable of $473,000,$119,000, a net increase in inventories of $337,000 and an increase in deposits of $8,000. The net decrease in accrued expensesaccounts receivable-trade and accounts payable was primarily due to timingreceivable-other of expense occurrence$127,000, a decrease in other assets of $9,000 and payables management, offset by our paymenta decrease in inventory of the $1.0 million contract cancellation settlement accrual in January. 

$18,000.


During the ninethree months ended September 30, 2016,March 31, 2019, operating activities used $4.2$1.9 million of cash, primarily resulting from our net loss of $7.2$2.4 million partially offset by non-cash charges of $3.0 million and by cash provided by changes in our operating assets and liabilities of $62,000.$48,000 and by non-cash charges of $368,000, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributedattributable to research and development activities and our selling, general and administrative expenses, as we generated limited research grant and licensingproduct revenue during the period. Net cash providedused by changes in our operating assets and liabilities for the ninethree months ended September 30, 2016March 31, 2019 consisted primarily of a $175,000 decrease in deferred revenue related to our license agreement with Neogen and a $202,000 decrease in accrued expenses and accounts payable. The decreasenet increase in accrued expenses and accounts payable was dueof $136,000 and a decrease in deposits of $1,000 offset by an increase in inventory of $74,000, an increase in receivables of $11,000, an increase in prepaid expenses of $3,000 and a decrease in deferred rent of $1,000.

Investing Activities.

For the three months ended March 31, 2020, we generated $40,000 in net cash related to increased paymentsinvesting activities as a result of the receiptsales of cash raised in financing activities.

Investing Activitiesfixed assets.

 

For the ninethree months ended September 30, 2017,March 31, 2019, we used $3.8 million$11,000 in net cash related to investing activities consisting of $2.9 million of purchases in securitiesdue to be held to maturity and $885,000 in purchases of property and equipment.

 

For the nine months ended September 30, 2016, we used $54,000 of cash in investing activities, consisting of purchases of property and equipment.

Financing ActivitiesActivities.

 

During the ninethree months ended September 30, 2017, net cash generated from financing activities was $294,000 as a result of $437,000 of proceeds from the issuance notes payable offset by payments of $66,000 related to notes payable and notes payable related party and $77,000 in payments of capital lease obligations.

During the nine months ended September 30, 2016,March 31, 2020, net cash provided by financing activities was $5.5$1.4 million as a result of $6.2 million of proceeds from the issuance of shares of common stock in our rights offering discussed elsewhere in this prospectus, $326,000 of proceeds received from our issuance of notes payable, $896,000 of proceeds received from the issuance of Series B convertible preferredcommon stock of $1.4 million offset by $34,000 related to payments of finance lease obligations and $449,00014,000 of payments of notes payable.

During the three months ended March 31, 2019, net cash used by financing activities was $15,000 as a result of payments of $32,000 related to notes payable and $19,000 in payments of finance lease obligations, offset by proceeds received from the exercise of stock options, allwarrants of which were partially offset by payments of $1.6 related to the notes, payable, notes payable related party and convertible notes payable, $16,000 of capital lease repayments and $801,000 of deferred offering cost payments.$36,000.

 

Recent DevelopmentsOff-Balance Sheet Arrangements

 

NoneNone.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

 


While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.


Revenue Recognition

 

We recognize revenue in accordanceEffective January 1, 2018, the Company adopted ASC 606 —Revenue from Contracts with Customers(“ASC 606”).Under ASC 606, the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”), Topic 605, Revenue Recognition. Accordingly, we recognizeCompany recognizes revenue from the commercial salesales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 —Revenue Recognition(“ASC 605”).Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of the fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The performance obligations identified by the Company under Accounting Standards Codification (“ASC”) Topic 606, Revenue From Contracts With Customers, are straightforward and similar to the unit of account and performance obligation determination under ASC Topic 605,Revenue Recognition.

 

We have generated revenue from a license agreement with a strategic partner pursuant to which we had granted to such partner the exclusive license in North America to manufacture, distribute and sell commercial control products based on our intellectual property, which includes ContraPest, for the later of 10 years or the expiration of the patent for ContraPest (if issued).

The license agreement was subsequently terminated on January 23, 2017.

When we receive non-refundable, upfront license fee payments for the exclusive rights to licensing our intellectual property, management determines if such license has stand-alone value. Since management determined that the license to our intellectual property did not have stand-alone value, we recognized revenue attributable to that license on a straight-line basis over the estimated related performance period. Any changes in the estimated period of performance will be accounted for prospectively as a change in estimate.

Our licensing agreement also provided for a future fixed amount of contingent milestone payments and contingent sales-based royalties to be received upon the achievement of milestone events. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved and the milestone payments are due and collectible. A milestone is considered substantive when the consideration payable to us for such milestone has all of the following characteristics: (1) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (2) the event can only be achieved based in whole or part on either our performance or a specific outcome resulting from our performance; and (3) if achieved, the event would result in additional payments being due to us. In making this assessment in the future, we will consider all facts and circumstances relevant to the arrangement, including whether any portion of the milestone consideration is related to future performance or deliverables. In addition, we will account for sales-based royalties as revenue upon achievement of certain sales milestones. 

Stock-Based Compensation

 

We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 — Stock Compensation (“ASC 718”). We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.

 

We recorded stock-based compensation expense of approximately $2.8 million$151,000 and $2.4 million$252,000 for the ninethree months ended September 30, 2017March 31, 2020 and 2016,2019, respectively. We expect to continue to grant stock options and other equity-based awards in the future and continue to the extent that we do, ourrecognize stock-based compensation expense recognized in future periods will likely increase.periods.

 

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:

 

 Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.

 


 Expected volatility. Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.

 

 Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.

 

 Expected dividend. The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.

 

 Expected forfeitures. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.

Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock

 

As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. Prior to our initial public offering in December 2016, in the absence of an active market for our common stock, we previously utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of our common stock. 

 

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:

 

  Three Months Ended
September 30
  Nine Months Ended
September 30,
 
  2017  2016  2017  2016 
Research and development $85  $135  $269  $309 
General and administrative  861   798   2,549   2,097 
Total stock-based compensation expense $946  $933  $2,818  $2,406 
  Three Months Ended
March 31,
 
  2020  2019 
  (in thousands) 
Selling, general and administrative expenses $148  $243 
Research and development expense  3   9 
Total stock-based compensation expense $151  $252 

 

The intrinsic value of stock options outstanding as of September 30, 2017 is $183,000, of which $968,000 and $(785,000) would have been related to stock options that were vested and unvested, respectively, at that date.March 31, 2020 was $0.

 

Emerging Growth Company Status

 

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

 


Item 3.Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintainconducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act), under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures that(as defined in Rule 13a-15(e)) as of the end of the period covered by this report.

These disclosure controls and procedures are designed to ensure that the information required to be disclosed in theour reports that we fileare filed or submitsubmitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to our management, including our Chief Executive Officerthe principal executive and Chief Financial Officer (or Acting Principal Financial Officer, as the case may be),principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management conducted an evaluation (pursuant to Rule 13a-15(b)) of

Based on the Exchange Act, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)) as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that ourthese disclosure controls and procedures were effective as of the end of the period covered by this report.

 

Changes in Internal Control over Financial Reporting

There werewas no changeschange in our internal control over financial reporting that occurred during the three-month periodquarter ended September 30, 2017March 31, 2020, that havehas materially affected, or areis reasonably likely to materially affect, our internal control over financial reporting.


PART II. OTHER INFORMATION

 

Item 1.Legal Proceedings

 

The Company may be subject toFor information regarding legal proceedings in which we are involved, see Note 12 — Commitments and claims arising from contracts or other matters from timeContingencies under the subsection titled “Legal Proceedings” in our Notes to timeCondensed Financial Statements in the ordinary coursePart I, Item 1 of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effectthis Quarterly Report on its financial position, results of operations or liquidity.Form 10-Q.

 

Item 1A.Risk Factors

 

Except as detaileddiscussed below, and disclosed in subsequently filed Quarterly Reports on Form 10-Q, there have been no material changes in the risk factors set forth in Part I, Item 1A, “Risk Factors” in our 2019 Annual Report on Form 10-K/A forReport.

The impacts of the year ended December 31, 2016.

Depending on the commercial success of ContraPest, we may require additional capital to fund our operations. Failure to obtain this necessary capital if needed may force us to delay, limit, or terminate our product development efforts or other operations.

Developing product candidates, including conducting experiments and field studies, obtaining and maintaining regulatory approval and commercializing any products later approved for sale, is a time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance our commercialization activities. We plan to substantially expand our operations, and as a result of many factors, some of which may be currently unknown to us, our expenses may be higher than expected. Securing additional financing may divert our management from their day-to-day activities, which maycoronavirus pandemic could adversely affect our ability to developbusiness, and commercializeother similar crises could result in similar or other harms.

The outbreak of the novel coronavirus (COVID-19) pandemic has resulted in widespread travel and transportation restrictions and closures of commercial spaces, industrial facilities and other spaces and businesses in and across the United States and the world, including in the locations we operate or target sales. As a result, our product candidates, including ContraPest.business has been impacted and we could face continued or more adverse effects. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, weour results and financial condition may be required to:

Significantly delay, scale back or discontinue the development or commercialization of our product candidates, including ContraPest;

Seek strategic partners for the manufacturing, sales and distribution of ContraPest or any of our other product candidates at an earlier stage than otherwise would be desirable or on termsadversely affected by federal or state legislation (or other similar laws, regulations, orders or other governmental or regulatory actions or best practices) that are less favorable than might otherwise be available; and
Relinquish, or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.

The occurrence of any of the events described above would have a material adverse effect on our business, operating results and prospects andimpose new restrictions on our ability to develop our product candidates.


If securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable research or other information aboutoperate our business or customers to operate their businesses. For example, our stock pricesales and trading volumetechnical field forces have been restricted from traveling, which adversely affects our ability to sell our products and complete field studies. While we have implemented cautionary procedures at our manufacturing facility, there may be disruptions to our ability to manufacture due to “stay at home” orders or additional workplace controls. Our customers may be less inclined or unable to purchase our products or continue product studies due to restrictions under which they may be operating. Those restrictions are more severe in some jurisdictions, such as California. If financial markets continue to tighten, we may have more limited ability to raise necessary financing. We source some of our critical raw materials from Asia, and the coronavirus has caused supply chain disruptions, which could decline.limit a timely supply of materials. Each of these could have negative effects on our business, results of operations, financial condition and cash flows. Even if the coronavirus pandemic passes, another crisis with similar effects could develop and harm our business, financial results and liquidity.

 

The trading market fordegree to which COVID-19 may impact our common stock may depend on the research, reports and other information that securities or industry analysts, or other, third party sources of information, publish about us or our business. We do not have any control over these analysts or other, third party sources of information, and from time to time inaccurate or unfavorable research or other information about our business, financial condition, results of operations and stock ownershipfinancial condition is unknown at this time and will depend on future developments, including the ultimate severity and the duration of the pandemic, and further actions that may be published. We cannot assure that analysts will cover ustaken by governmental authorities or provide favorable coverage. If onebusinesses or more ofindividuals on their own initiatives in response to the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline. If incorrect or misleading information is disseminated publicly by third parties about us, our stock price could decline.pandemic.

 

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

 

Unregistered SalesThere were no unregistered sales of Equity Securities and Use of Proceedsthe Company’s equity securities during the quarter ended March 31, 2020, that were not previously disclosed in a Current Report on Form 8-K.

Item 3.Defaults Upon Senior Securities

 

None.

 

Item 4.Mine Safety Disclosures

Use of Proceeds from Public Offering of Common Stock

Not applicable.

 

In December 2016, we closed our initial public offering (“IPO”), in which we sold 1,875,000 shares of common stock at a price to the public of $8.00 per share. No shares were sold in connection with the underwriters’ option to purchase additional shares. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-213736), which was declared effective by the SEC on December 7, 2016. We raised approximately $12.6 million in net proceeds after deducting underwriting discounts and commissions of approximately $1.1 million and offering expenses of approximately $1.3 million. Using the proceeds from the IPO, on December 13, 2016, we paid $175,890 to the holder of all of our shares of Series A convertible preferred stock for its agreement to waive all accrued dividends on the Series A convertible preferred stock and convert all of its shares of Series A convertible preferred stock into common stock immediately prior to the consummation of the IPO. No payments were made by us to directors, officers or persons owning 10% or more of our capital stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries. There has been no material change in the planned use of proceeds from our IPO as described in the final prospectus issued in connection with the IPO.  We have invested the remaining proceeds in accordance with our board approved investment policy, which provides for investments in obligations of the U.S. government, money market instruments, registered money market funds and corporate bonds. The managing underwriter of our IPO was Roth Capital Partners, LLC and co-managing underwriters were Craig-Hallum Capital Group LLC and Aegis Capital Corp. 

Item 5.

Other Information

 None.

None. 


Item 6.Exhibits

 

The exhibits listed in the Index to Exhibits are filed or incorporated by reference as part of this Quarterly Report on Form 10-Q.

INDEX TO EXHIBITS

 

Exhibit
Number
 Filed or
Furnished Herewith

Incorporated by Reference

DescriptionForm Filing
Date
Exhibit File No.
3.1 Amended and Restated Certificate of Incorporation S-1/A 10/20/20163.3 333-213736
         
3.2Amended and Restated Bylaws S-1 9/21/20163.5 333-213736
         
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X      
         
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X      
         
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X      
         
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X      
         
101.INSXBRL Instance DocumentX      
         
101.SCHXBRL Taxonomy Extension SchemaX      
         
101.CALXBRL Taxonomy Extension Calculation LinkbaseX      
         
101.DEFXBRL Taxonomy Extension Definition LinkbaseX      
         
101.LABXBRL Taxonomy Extension Label LinkbaseX      
         
101.PREXBRL Taxonomy Extension Presentation LinkbaseX      

Exhibit    Filed or
Furnished
    Incorporated by Reference
Number  Description Herewith Form  Filing Date Exhibit  File No.
                
3.1  Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment to the Amended and Restated Certificate of Incorporation   10-K  

3/17/2020

  3.1  

001-37941

                 
4.1  Form of Warrant   8-K  1/28/2020  4.1   001-37941
                 
4.2  Form of Placement Agent Warrant   8-K  1/28/2020  4.2   001-37941
                 
4.3  Form of Warrant   8-K  3/6/2020  4.1  001-37941
                 
4.4  Form of Placement Agent Warrant   8-K  3/6/2020  4.2   001-37941
                 
10.1+  Employment Letter Agreement by and between the Company and Kim Wolin dated January 28, 2020   S-1/A  2/13/2020  10.7  333-236302
                 
10.2+  Employment Letter Agreement by and between the Company and Steven Krause, dated January 12, 2020   10-K/A  4/21/2020  10.1  001-37941
                 
10.3  Form of Securities Purchase Agreement, dated as of January 23, 2020, between the Company and each purchaser thereto   8-K  1/28/2020  10.1  001-37941
                 
10.4  Form of Securities Purchase Agreement, dated as of March 4, 2020, between the Company and the purchaser thereto   8-K  3/6/2020  10.1  001-37941
                 
31.1  Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 X           
                 
31.2  Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 X           
                 
32.1  Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X           
                 
32.2  Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X           
101.INS  XBRL Instance Document X           
101.SCH  XBRL Taxonomy Extension Schema Document X           
101.CAL  XBRL Taxonomy Extension Calculation Linkbase Document X           
101.DEF  XBRL Taxonomy Extension Definition Linkbase Document X           
101.LAB  XBRL Taxonomy Extension Label Linkbase Document X           
101.PRE  XBRL Taxonomy Extension Presentation Linkbase Document X           

 

+Indicates a management contract or compensatory plan.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

SENESTECH, INC.

(Registrant)

   
Dated: November 8, 2017May 15, 2020By:/s/ Loretta P. Mayer, Ph.D.Kenneth Siegel
  Loretta P. Mayer, Ph.D.Kenneth Siegel
  Chair of the Board, Chief Executive Officer and
Chief Scientific Officer
   
Dated: November 8, 2017May 15, 2020By:/s/ Thomas C. Chesterman
  Thomas C. Chesterman
  Chief Financial Officer and Treasurer

 

41